COMPOSITIONS AND METHODS FOR PACE 4 AND 4.1 GENE AND POLYPEPTIDES IN CELLS

Abstract: Compositions and methods are provided for endopeptidases and their production, and for enhanced efficiencies of processing heterologous precursor polypeptides to mature polypeptides. These compositions and methods utilize recombinant PACE 4 and 4.1, mammalian endopeptidases that are specific for dibasic amino acid sites. Therapeutic compositions and methods employing PACE 4 or 4.1 or their inhibitors are also provided.

Description: COMPOSITIONS AND METHODS FOR PACE 4 AND 4.1 GENE AND POLYPEPTIDES IN CELLS BACKGROUND OF THE INVENTION 1. Field of the Disclosure This invention relates generally to proteins and their production in recombinant host cells. More particularly, it relates to polynucleotide sequences that encode novel paired basic amino acid converting enzymes (generically referred to as "PACE," with the two new enzymes being PACE 4 and 4.1), to the production of PACE 4 and 4.1 in transformed cells, and to compositions comprising the PACE 4 and 4.1 enzymes. Materials and methods are also provided for the production of mature forms of proteins from heterologous precursor polypeptides using PACE 4 or 4.1, which are expressed in recombinant host cells. 2. Description of Related Art Many eukaryotic proteins synthesized in bacteria fold incorrectly and, consequently, exhibit low specific activities. Post-translational proteolysis is a common mechanism required for the synthesis of biologically active proteins and peptides in all eukaryotes examined, including yeast (R.S. Fuller et al., (1988), Ann. Rev. Phvsiol. 50:345), invertebrates (R.H, Scheller et al. (1983), Cell 32:7), and mammalian cells (J. Douglass et al. (1984), Ann. Rev. Biochem. 53:665: W.S. Sossin et al. (1989), Neuron 2, 1407). One of the early events in precursor protein maturation is endoproteolysis at the carboxyl side of pairs of basic amino acid sequences (e.g. -LysArg- and -ArgArg-). This kind of endoproteolytic cleavage was initially infeιτed from the sequences of several endocrine and neuroendocrine precursor proteins and was first proposed from studies of proinsulin (D.F. Steiner et al. (1968), Science 157:697; R.E. Chance et al. (1968), Science 161:165) and the ACTH/β-endorphin precursor, proopiomelanocortin (POMCXM. Chretien and CH. Li (1967), Can. J. Biochem. 45:1163). Subsequent studies have revealed a broad spectrum of precursor proteins that require SUBSTITUTE SHEET endoproteolysis at pairs of basic amino acids to yield mature peptides including serum factors (A.K. Bentley et al. (1986), Cell 45:343), viral proteins (CM. Rice et al. (1986), Virology 151:1; CM. Rice et al. (1985), Science 229:726; J.M. McCune et al. (1988), CeU 53:55), growth factors (L.E. Gentry et al- (1988). Mol. Cell Biol. 8:4162: K. Sharpies et a (1987), DNA 6:239; M. Yanagisawa et al. (1988), Nature 332:411: and Gray et al. (1983), Nature 303:722) and receptors (Y. Yosimasa (1988), Science 240:784). Several candidate enzymes that are capable of cleaving at single or paired basic residues in vitro have been proposed as authentic mammalian precursor endoproteases. See, for example, Y.P. Loh and H. Gainer, in Brain Peptides. D.T. Rrieger, MJ. Brownstein, J.B. Martin, Eds. (Wiley-Interscience, New York, 1983), pp.76-116; M. Chretien, et al. in Cell Biology of the Secretory Process (Karger, Basel, Switzerland, 1983), pp.214-246; AJ. Mason, et al- (1983), Nature 303:300; P.J. Isackson et al. (1987). J. CeU. Biochem. 33:65: I. Lindberg et al., (1984). J. Neurochem 42:1411: J.A. Cromlish et al. (1986), J. Biol. Chem. 261: 10850; K. Docherty et aL (1984), J. Biol. Chem. 259:6041: T.C Chang and Y.P. Loh (1984), Endocrinology 114. 2092; B.P. Noe et al. (1984), J. CeU. Biol. 99:578: U.P. Loh (1986). J. Biol. Chem. 261:11949: H.W. Davidson et al. (1987). Biochem. J. 246:279: P. Gluschankof et al. (1987), Biol. Chem. 262:9615: C Clamigrand et al. (1987). Biochem 26:6018: S.O. Brennan and RJ. Peach (1988), FEBS Letters 229: 167; R.S. FuUer et al. (1989), Proc. Natl. Acad. Sci. USA 86:1434: K. Mizuno et al. (1989), Biochem. Biophvs. Res. Comm. 159:305: I.C. Bathurst et al. (1987), Science 235:348; and G. Thomas et al- (1988), Science 241:226. However, none of these candidate activities have been shown to be a bona fide precursor cleaving endoprotease in vivo. The yeast enzyme Kex2, a membrane-bound, Ca 2+ -dependent serine protease (K. Mizuno et al. (1988), Biochem. Biophvs. Res. Commun. 156:246; R.S. FuUer et al. (1989), Proc. Natl. Acad. Sci. USA 86:1434), has been considered to be a prototypic proprotein convertase. The Kex2 endoprotease, which is encoded by the KEX2 gene, functions late in the secretory pathway of Saccharomyces cerevisiae, and cleaves the polypeptide chains of prepro-kiUer toxin and prepro-α-factor at the paired basic amino acid sequences Lys-Arg and Arg-Arg (D. JuUus et al. (1984), Cell 36:309). Furthermore, co-expression of the KEX2 gene with POMC in BSC-40 ceUs (a ceU line SUBSTITUTE SHEET which is incapable of processing this peptide precursor) resulted in the generation, by proteolysis at pairs of basic amino acids, of authentic product peptides, including b- LPH and β-endorphin (Thomas et al. (1988), id.). Two human DNA sequences, fur and PC2, share some structural homology with each other and with the KEX2 gene sequence. A.M.W. van den Ouweland et al. (1990), Nucleic Acids Res. 18:664 (presenting a cDNA coding sequence for fur; the cDNA sequence of Figure 1 differs from this sequence in the region encoded by nucleotides 1-238); R.S. Fuller et al.. Science 246:482 (1989); S.P. Smeekens (1990), J. Biol. Chem. 265:2997. The fur locus was initiaUy identified by its proximity to the fes/fES proto-oncogene (A.J.M. Roebroek' et al. (1986). EMBO J. 5:2197). PC2 was identified by amplification of a human insulinoma Ubrary by the polymerase chain reaction using KEX2-derived primers; it shares a partial homology with Kex2, especially in the putative active site domains (S.P. Smeekens and D.F. Steiner, (1990) J. Biol. Chem. 265:2997). Another related cDNA encoding a protein variously caUed PCI (Seidah et al. (1991) Mol. Endocrinol. 5:111-122) or PC3 (Smeekens et al- (1991) Proc. Natl. Acad. Sci. USA 88:340-344) has been isolated from murine pituitary ceUs. PC1 PC3 also shares amino acid siπύlarity with KEX2, particularly in the putative catalytic domains. Recently a functional activity has been demonstrated for PC2 and PC1/PC3, using as a substrate the prohormone proopiomelanocortin (POMC). In the anterior lobe of the pituitary, POMC is processed to yield the hormones ACTH, β-lipotropin, and β-endorphin, while in the intermediate lobe it is processed to yield α-melanocyte stimulating hormone (α-MSH) and variant forms of ACTH and β-Upotropin. PC1/PC3 expressed in processing deficient cells cleaved POMC to give ACTH, but was less efficient in cleaving β-lipotropin to give β-endorphin. This is simUar to the activity found in pituitary corticotrophic cells. Coexpression of PC2 and PC1/PC3 efficiently converted β-lipotropin, as is found in melanotrophic cells. Coexpression of POMC and PC2 in adrenomeduUary chromaffin ceUs resulted in secretion of β-endorphin and α- MSH. Therefore PC1/PC3 and PC2 have differing substrate selectivities which yield physiologically relevant processed polypeptides. SUBSTITUTE SHEET RELEVANT LITERATURE AVTV, H., and LEDER, P. (1972). Purification of biologically active globin messenger RNA by chromatography on oUgothymidyUc acid-ceUulose. Proc. Natl. Acad. Sci. USA 69. 1408-1412. BARR, P.J. (1991). Mammalian subtiUsins: The long-sought dibasic processing endo- proteases. Cell 66, 1-3. BARR, P.J., MASON, O.B., LANDSBERG, K.E., WONG, P.A., K1EFER, M.C, and BRAKE, A.J. (1991). cDNA and gene structure for a human subtUisin-like protease with cleavage specificity for paired basic amino acid residues. DNA CeU Biol. 10, 319-328. BARR, P.J., THAYER, R.M., LAYBOURN, P., NAJARIAN, R.C., SEELA, F., and TOLAN, D.R. (1986). 7-Deaza-2'-Deoxyguanosine-5'-Triphosphate: Enhanced- resolution in M13 dideoxy sequencing. Biotechniques 4, 428-432. BENJANNET, S., RONDEAU, N., DAY, R., CHRETIEN, M., and SEIDAH, N.G. (1991). PCI and PC2 are proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of basic residues. Proc. Natl. Acad. Sci. USA 88, 3564-3568. BRESNAHAN, P.A., LEDUC, R., THOMAS, L., THORNER, J., GIBSON, H.L., BRAKE, A.J., BARR, P.J., and THOMAS, G. (1990). Human fur gene encodes a yeast KEX-2 like endoprotease that cleaves pro-b-NGF in vivo. J. Cell. BioL 111, 2851-2859. CHIRGWIN, J.M., PRZBYLA, A.E., MACDONALD, R.J., AND RUTTER, W.J. (1979). Isolation of biologicaUy active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18, 5294-5299. SUBSTITUTE SHEET CHRISTIE, D.L., BATCHELOR, D.C, and PALMER, D.J. (1991). Identification of kex2 related proteases in chromaffin granules by partial amino acid sequence analysis. J. Biol. Chem. 266. 15679-15683. 5 FEINBERG, A.P., and VOGELSTEIN, B. (1984). A technique for radiolabeUng DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 137, 266- 267. FREEMAN, G.J., CLAYBERGER, C, DEKRUYFF, R., ROSENBLUM, D.S., and 10 CANTOR, H. (1983). Sequential expression of new gene programs in inducer T-cell clones. Proc. Natl. Acad. Sci. USA 80. 4094-4098. FRICKER, L.D., DAS, B., and ANGELETTI, R.H. (1990). Identification of the pH- dependent membrane anchor of carboxypeptidase E (EC 3.4.17.10). J. Biol. Chem. 15 265, 2476-2482. FULLER, R.S., BRAKE, A.J., and THORNER, J. (1989). IntraceUular targeting and structural conservation of a prohormone-processing endoprotease. Science 246, 482-- 486. 20 GILBERT, W. (1985). Genes-in-pieces revisited. Science 228, 823-824. HATSUZAWA, K., HOSAKA, M., NAKAGAWA, T., NAGASE, M., SHODA, A., MURAKAMI, K., and NAKAYAMA, K. (1990). Structure and expression of mouse 25 furin. a yeast KEX2-related protease. J. Biol. Chem. 265, 22075-22078. KIEFER, M.C, JOH, R.S., BAUER, D.M., and ZAPF, J. (1991). Molecular cloning of a new human insuUn-like growth factor binding protein. Biochem. Biophvs. Res. Comm. 176, 219-225. 30 SUBSTITUTE SHEET KIEFER, M.C., MASIARZ, F.R., BAUER, D.M., and ZAPF, J. (1991). Identification and molecular cloning of two new 30-kDa insulin-like growth factor binding proteins isolated from adult human serum. J. Biol. Chem. 266, 9043-9049. KORNER, J., CHUN, J., HARTER, D., and AXEL, R. (1991). Isolation and functional expression of a mammalian prohormone processing enzyme, murine prohormone convertase 1. Proc. Natl. Acad. Sci. USA 88, 6834-6838. HOSAKA, M., NAGAHAMA, M., KIM^W.-S., WATANABE, T., HATSUZAWA, K., IKEMIZU, J., MURAKAMI, K., and NAKAYAMA, K. (1991). Arg-X-Lys/Arg-Arg motif as a signal for precursor cleavage catalyzed by furin within the constitutive secretory pathway. J. Biol. Chem. 266, 12127-12130. LEHRACH, H., DIAMOND, D., WOZNEY, J.M., and BOEDTKER, H. (1977). RNA molecular weight determinations by gel electrophoresis under denaturing conditions, a critical re-examination. Biochemistry 16, 4743. MISUMI, Y., ODA, K., FUJTWARA, T., TAKAMI, N., TASHIRO, K., and IKEHARA, Y. (1991). Functional expression of furin demonstrating its intraceUular localization and endoprotease activity for processing of proalbumin and complement pro-C3. J. Biol. Chem. 266, 16954-16959. PINKEL, D., LANDEGENT, J., COLLINS, C, FUSCOE, J., SEGRAVES, R., LUCAS, J., and GRAY, J. (1988). Fluorescence in situ hybridization with human chromosome specific Ubraries: Detection of trisomy 21 and translocations of chromosome 4. Proc. Natl. Acad. Sci. USA 85. 9138-9142. ROEBROEK, A.J.M., SCHALKEN, J.A., BUSSEMAKERS, M.J.G., VAN HEERD HUIZEN, H., ONNEKINK, C, DEBRUYNE, F.M.J., BLOEMERS, H.P.J., and VAN DE VEN, WJ.M. (1986). Characterization of human c-fes/fps reveals a new transcription unit (fur) in the immediately upstream region of the proto-oncogene. Mol. Biol. Rep. 11, 117-125. SUBSTITUTE SHEET SAIKI, R.K., SCHARF, S., FALOONA, F., MULLIS, K.B., HORN, G.T., ERLICH, H.A., and ARNHEIM, N. (1985). Enzymatic ampUfication of b-Globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230, 1350-1354. SAMBROOK, J., MAN1ATIS, T., FRITSCH, E.F. (1989). Molecular Cloning: A Laboratory Manual. (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). SCHALKEN, J.A., ROEBROEK, A.J.M., OOMEN, P.P.C.A., WAGENAAR, S.SC, DEBRUYNE, F.M.J., BLOEMERS, H.P.J., and VAN DE VEN, W.J.M. (1987). fur Gene expression as a discriminating marker for small ceU and nonsmaU ceU lung carcinomas. J. Clin. Invest. 80, 1545-1549. SEIDAH, N.G., GASPAR, L., MION, P., MARCINKIEWICZ, M., MBIKAY, M., and CHRETIEN, M. (1990). cDNA sequence of two distinct pituitary proteins homologous to Kex2 and furin gene products: Tissue-specific mRNAs encoding candidates for pro¬ hormone processing proteinases. DNA Cell Biol. 9, 415-424. SHENNAN, K.I.J., SEAL, A.J., SMEEKENS, S.P., STEINER, D.F., and DOCHERTY, K. (1991). Site-directed mutagenesis and expression of PC2 in microinjected xenopus oocytes. J. Biol. Chem. SMEEKENS, S.P., AVRUCH, A.S., LAMENDOLA, J., CHAN, S.J., and STEINER, D.F. (1991). Identification of a cDNA encoding a second putative prohormone convertase related to PC2 in AtT20 cells and islets of Langerhans. Proc. Natl. Acad. Sci. USA 88, 340-344. SMEEKENS, S.P., and STEINER, D.F. (1990). Identification of a human insulinoma cDNA encoding a novel mammatian protein structuraUy related to the yeast dibasic processing protease Kex2. J. Biol. Chem. 265, 2997-3000. SUBSTITUTE SHEET THOMAS, P.S., (1980). Hybridization of denatured RNA and smaU DNA fragments transferred to nitroceUulose. Proc. Natl. Acad. Sci. USA 77. 5201. THOMAS, L., LEDUC, R., THORNE, B.A., SMEEKENS, S.P., STEINER, D.F., and THOMAS, G. (1991). KEX2-like endoproteases PC2 and PC3 accurately cleave a model prohormone in mammaUan ceUs: Evidence for a common core of neuroen- docrine processing enzymes. Proc. Natl. Acad. Sci. USA 88, 5297-5301. TOMKINSON, B. and JONSSON, A.-K. (1990). Characterization of cDNA for human tripeptidyl peptidase U: The N-terminal part of the enzyme is sim ar to subtiUsin. Biochem. 30. 168-174. VAN DE VEN, W.J.M., VOORBERG, J., FONTUIN, R., PANNEKOEK, H., VAN DEN OUWELAND, A.M.W., VAN DUUNHOVEN, H.L.P., ROEBROEK, A.J.M., and SIEZEN, R.J. (1990). Furin is a subtiUsin-like proprotein processing enzyme in higher eukaryotes. Mol. Biol. Rep. 14, 265-275. VON HEIJNE, G. (1986). A new method for predicting signal sequence cleavage sites. Nucl. Acids Res. 14, 4683-4690. WANG, P.H., DO, Y.S., MACAULAY, L, SHINAGAWA, T., ANDERSON, P.W., BAXTER, J.D., and HSUEH, W.A. (1991). Identification of renal cathepsin B as a human prorenin-processing enzyme. 266, 12633-12638. WISE, R.J., BARR, P.J., WONG, P.A., KIEFER, M.C., BRAKE, A.J., and KAUFMAN, R.J. (1990). Expression of a human proprotein processing enzyme: Correct cleavage of the von WiUebrand precursor at a paired basic amino acid site. Proc. Natl. Acad. Sci. USA 87, 9378-9382. YAN1SCH-PERRON, C, VIEIRA, L., and MESSING, J. (1985). Improved M13 phage cloning vectors and host strains. Nucleotide sequences of the M13mpl8 and pUC19 vectors. Gene 33, 103-119. SUBSTITUTE SHEET ZAPF, J., KIEFER, M., MERRYWEATHER, J., MASIARZ, F., BAUER, D.. BORN. W., FISCHER, J.A., and FROESCH, E.F. (1990). Isolation from adult human serum of four insulin-like growth factor (IGF) binding proteins and molecular cloning of one of them that is increased by IGF1 administration and in extra-pancreatic tumor hypoglycemia. J. Biol. Chem. 265, 14892-14898. SUMMARY OF THE INVENTION Recombinant polynucleotides are provided for the expression of a novel mammaUan endopeptidase, PACE 4, and its alternative form, PACE 4.1, which are involved in the production of mature polypeptides from precursor polypeptides by cleavage at pairs of basic amino acids (e.g., -LysArg-, -LysLys-, and -ArgArg-). These recombinant polynucleotides can be used for enhanced intraceUular or extraceUular production of PACE 4 and 4.1 in transformed ceUs. Additionally, efficient conversion of co-expressed heterologous polypeptides having processing sites recognized by PACE 4 or 4.1 can produce desired mature forms of those polypeptides. Purified PACE 4 and 4.1 are also provided. These have utiHty for commercial and pharmaceutical purposes. The present invention includes vectors, transformed mammaUan, insect, and microorganism ceUs, methods for producing PACE 4 and 4.1, methods for expressing and secreting a desired mature polypeptide from a heterologous precursor polypeptide using PACE 4 or 4.1, purified PACE 4 and 4.1, a pharmaceutical preparation containing PACE 4 or 4.1, and therapeutic methods involving administration of PACE 4 or 4.1, or inhibitors of PACE 4 and 4.1. DESCRIPTION OF THE DRAWING Figure 1 shows the composite cDNA sequence encoding PACE 4 (SEQ ID NO: 1), and the amino acid sequence of the translation product encoded therein. Figure 2 shows the composite cDNA sequence encoding the alternate splicing region of PACE 4.1 (SEQ ID NO: 3), and the amino acid sequence of the translation product encoded therein. Shown are the additional cDNA sequence encoding 16 amino acids, termination codon, and 3 '-untranslated region which comprise the truncated cDNA and encoded protease amino acid sequence of PACE 4.1 (SEQ ID NO: 4). The SUBSTITUTE SHEET sequence of PACE 4.1 is identical to that of PACE 4 through Lys 471. The beginning of the divergence in cDNA sequence is indicated by an arrow. Figure 3 shows the DNA sequence of the homolog of exon 12 of the furin/PACE gene (SEQ ID NO: 5) (Ban * et al., 1991). This sequence contains the intron/exon splice junction for commitment to either PACE 4 (SEQ ID NO: 1) or PACE 4.1 (SEQ ID NO: 1) & (SEQ ID NO: 3) mRNA. This exon sequence corresponds to PACE 4 (SEQ ID NO: 1) residues Ser 473 to Pro 510. Figure 4 provides a restriction map, clone diagrams, and composite diagram for PACE 4. The composite diagram indicates the amino terminal signal sequence by a shaded box, and the remainder of the coding region by the hatched box. Individual clones are identified above the composite diagram. Restriction endonucleases are abbreviated as foUows: B, BamHI; G, Bglll; R, EcoRI; Sm, Smal; Sp, SphI. Each clone has synthetic EcoRI and B iπ sites at the 5' and 3' termini. Figure 5 provides a restriction map, clone diagrams, and composite diagram for PACE 4.L The composite diagram indicates the amino terminal signal sequence by a shaded box, and the remainder of the coding region by the hatched box. Individual clones are identified above the composite diagram. Restriction endonucleases are abbreviated as foUows: B, BamHI: G, BgLQ: R, EcoRI; Sm, Smal; Sp, SphI. Each clone has synthetic EcoRI and Bgiπ sites at the 5' and 3' termini. Figure 6 is a domain map of PACE 4 and 4.1, together with comparative maps for other dibasic endoproteases KEX2, furin PACE, PC2, and PCI/PC3. Active site Asp, His, Asn (Asp), and Ser residues are indicated as D, H, N (D), and S, respectively. Potential glycosylation sites are indicated by a diamond. Putative signal peptides (Sig), membrane-binding amphipathic heUces (AH), and transmembrane domains (TM) are indicated by soUd boxes. Cysteine-rich (CRR) and serine/threonine- rich (S/TRR) regions are indicated by hatched boxes. Proprotein regions are indicated by shaded boxes. Figure 7 shows a comparison among the amino acid sequences of the catalytic domains of PACE 4 (SEQ ID NO: 11) and 4.1 (SEQ ID NO: 11) (human) and other dibasic endoproteases KEX2 (yeast) (SEQ ID NO: 7), furin/PACE (human) (SEQ ID NO: 8), PC2 (human) (SEQ ID NO: 9), and PC1/PC3 (mouse) (SEQ ID NO: 10). Amino acids that are identical among three or more proteases are indicated. SUBSTITUTE SHEET Figure 8 shows Northern blot analysis of PACE 4 and 4.1. The blots in panels A and B contain human poly(A) + RNAs from various tissues, while those in panels C and D contain poly(A) + RNAs from human or hamster cultured cell Unes. Blots were hybridized with a PACE 4 specific probe (panels A and C) or a PACE 4.1 specific probe (panels B and D). Figure 9 shows in situ hybridization of cosmid DNA to metaphase chromosomes as revealed by fluorescence of FITC labeUed fur and Texas Red labelled PACE 4 gene probes. DETAILED DESCRIPTION OF THE INVENTION I. Definitions As used herein, the term "PACE" is an acronym for paired basic amino acid converting enzyme. An enzyme belonging to the PACE family is a subtiUsin-Uke endopeptidase, i.e., a propeptide-cleaving enzyme, which exhibits specificity for cleavage at basic residues of a polypeptide, e.g., -lys-arg-, -arg-arg, or -lys-lys-; is stimulated by calcium ions; and is inhibited by phenylmethyl sulfonyl fluoride (PMSF). A cDNA that encodes a novel form of PACE, referred to herein as PACE 4, is presented in Figure 1. PACE 4 is derived from an animal cell, more specifically from a human cell. Previous applications, including U.S. Application Numbers 07/620,859, filed November 29, 1990; 07/621,443, filed November 29, 1990; and 07/621,457, filed November 30, 1990, herein incorporated by reference, disclose the isolation of a gene encoding a different form of PACE, also isolated from human ceUs. The present invention demonstrates that other forms of PACE exist and that they can be produced artificaUy. Thus, "PACE 4" refers to any of the naturally occurring forms, including the PACE 4 precursor protein shown in Figure 1, and various processed forms, including the mature PACE 4 polypeptide and modified proteins that have the properties of natural-sequence PACE 4. "Natural-sequence PACE 4" refers to the specific molecule having the sequence set forth in Figure 1 and the fragments and derivatives thereof defined in this specification. Polypeptide fragments that maintain the catalytic specificity of that enzyme are encompassed by the general term PACE 4. Additionally, analogs of PACE 4 are included within the definition of PACE 4, and SUBSTITUTE SHEET include truncated polypeptides (including fragments) and PACE 4-like polypeptides, e.g., mutants in which there are variations in the amino acid sequence that retain catalytic activity and preferably have a homology of at least 80%, more preferably 90%, and most preferably 95%, with the corresponding region of the PACE 4 sequence of Figure 1. TypicaUy, such analogs differ by only 1, 2, 3, or 4 amino acids. Examples include polypeptides with minor amino acid variations from the natural amino acid sequence of PACE 4; in particular, conservative amino acid replacements. Conservative replacements are those that take place within a famUy of amino acids that are related in their side chains. GeneticaUy encoded amino acids are generaUy divided into four famiUes: (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) non-polar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar = glycine, asparagine, glutamine, cystine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a siπύlar conservative replacement of an amino acid with a structuraUy related amino acid wiU not have a major effect on the enzymatic activity, especiaUy if the replacement does not involve an amino acid at the active site of the PACE-like polypeptide. As discussed elsewhere in this specification in detaU, a PACE 4 molecule of a variant type, referred to as PACE 4.1, has a sequence partiaUy identical with the sequence of PACE 4, and exhibits siπύlar enzymatic properties. PACE 4.1 is produced by alternate spUcing of mRNA, and encompasses the catalytic domain of PACE 4 truncated on the C-terminal side, to which is added an additional 16 amino acids comprising a novel C-terminus. Utilizing the sequence data in Figure 1, as weU as the denoted characteristics of a PACE molecule in general and those of PACE 4 and 4.1 in particular, it is within the skill of the art to obtain other PACE 4 or 4.1 polypeptides, or other DNA sequences encoding PACE 4 or 4.1. For example, the structural gene can be manipulated by varying individual nucleotides, wh e retaining the correct amino acid(s), or varying the nucleotides, so as to modify the amino acids, without loss of enzymatic activity. Nucleotides can be substituted, inserted, or deleted by known techniques, including, for example, in vitro mutagenesis and primer repair. The structural gene can be truncated SUBSTITUTE SHEET at its 3 '-terminus and/or its 5 '-terminus while retaining its endopeptidase activity. For example, PACE 4 as encoded in Figure 1 contains a cysteine-rich region (CRR), which it may be desirable to delete. It also may be desirable to remove the region encoding the signal sequence, and/or to replace it with a heterologous sequence. It may also be desirable to ligate a portion of the PACE 4 or 4.1 sequence (particularly that which includes the catalytic domain) to a heterologous coding sequence, and thus to create a fusion peptide with the enzymatic specificity of PACE 4. In designing such modifications, it is expected that changes to nonconserved regions of the PACE-type structure wUl have relatively smaUer effects on activity, whereas changes in the conserved regions, and particularly in or near the catalytic active site domains D, H, and S, are expected to produce larger effects. The comparison among catalytic domain sequences of yeast KEX 2, human PACE, human PC2, mouse PC1/PC3, and human PACE 4, given in Figure 7, provides guidance on amino acid substitutions which are compatible with catalytic activity. Amino acid residues which are conserved among PACE 4 and at least three of the four related proteins are important for good catalytic activity and are not expected to be candidates for substitution. A residue which shows conservative variations among PACE 4 and at least two of the four related proteins is expected to be capable of similar conservative substitution of the PACE 4 sequence. Siπύlarly, a residue which varies nonconservatively among PACE 4 and at least three of the four related proteins is expected to be capable of either conservative or nonconservative substitution. When designing substitutions to the PACE 4 or 4.1 sequence, replacement by an amino acid which is found in the comparable aUgned position of one of the four related proteins is especially preferred. In addition to the above, other open reading frames (ORFs) or structural genes encoding PACE 4 or 4.1 can be obtained and/or created from cDNA libraries from other animal cell sources. As used herein, the term "polypeptide" refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oUgopeptides, and proteins are included within the definition of polypeptide. This term also does not exclude post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for SUBSTITUTE SHEET example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids) and polypeptides with substituted linkages, as weU as other modifications known in the art, both naturaUy occurring and non-naturaUy occurring. The term "precursor polypeptide" denotes an expressed polypeptide which normaUy undergoes one or more posttranslational proteolytic cleavages to yield a biologicaUy active mature polypeptide. Included within the term "precursor polypeptide" are "prepropolypeptides" and "propolypeptides." A "prepeptide" is the portion of a precursor polypeptide which is removed by "signal peptidase" cleavage during translocation of the polypeptide into the endo- plasmic reticulum. The "prepeptide" region is usuaUy at or near the amino terminus. A "propeptide" is the portion of a precursor polypeptide which is removed by a "propolypeptide convertase" or "endopeptidase" (for example, Kex2 and PACE) during the maturation process of the polypeptide. Many proteins, such as plasma proteins, hormones, neuropeptides, and growth factors, are translated with an additional "propeptide" region located to the carboxy side of the prepeptide region. After cleavage of the prepeptide, the "propeptide" segment is cleaved by a site-specific endo¬ peptidase contributing to the maturation of the polypeptide. A "mature" form of a polypeptide has had a prepeptide and/or propeptide region removed. A polypeptide or amino acid sequence "derived from" a designated nucleic acid sequence refers to a polypeptide having an amino acid sequence identical to that of a polypeptide encoded in the sequence, or a portion thereof wherein the portion consists of at least 3-5 amino acids, and more preferably at least 8-10 amino acids, and even more preferably at least 11-15 amino acids, or which is immunologicaUy identifiable with a polypeptide encoded in the sequence. This terminology also includes a polypeptide expressed from a designated nucleic acid sequence. A polypeptide of the invention is not necessarily translated from a designated nucleic acid sequence, for example, the sequence in Figure 1. It can be generated in any manner, including, for example, chemical synthesis, expression of a recombinant expression system, or isolation from a ceU. A recombinant or derivative polypeptide of the invention can include one or more analogs of amino acids or unnatural amino acids in its sequence. Methods of inserting analogs of amino acids into a sequence are SUBSTITUTE SHEET known in the art. It also can include one or more labels, which are known to those of skiU in the art. The term "recombinant polynucleotide" as used herein intends a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide other than that to which it is linked in nature, or (3) does not occur in nature. The term "polynucleotide" as used herein refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, this term includes double- and single-stranded DNA and RNA. It also includes known types of modifications, for example, labels which are known in the art, methylation, "caps," substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), those containing pendant moieties, such as, for example proteins (including for e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylators, those with modified Unkages (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotide. A "repUcon" is any genetic element, e.g., a plasmid, a chromosome, a virus, a cosmid, etc. that behaves as an autonomous unit of polynucleotide repUcation within a cell; i.e., capable of replication under its own control. This can include selectable markers. A "vector" is a replicon in which a recombinant polynucleotide segment is attached, so as to bring about the replication and/or expression of the attached segment. "Control sequence" refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are Ugated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, generally, such control sequences include SUBSTITUTE SHEET promoters and transcription termination sequence. The term "control sequences" is intended to include, at a minimum, aU components whose presence is necessary for expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences. "Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is Ugated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences. An "open reading frame" (ORF) is a region of a polynucleotide sequence which encodes a polypeptide; this region can represent a portion of a coding sequence or a total coding sequence. A "coding sequence" is a polynucleotide sequence which is translated into a polypeptide, usuaUy via mRNA, when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5 '-terminus and a translation stop codon at the 3'-terminus. A coding sequence can include, but is not limited to, cDNA, and recombinant polynucleotide sequences. "PCR" refers to the technique of polymerase chain reaction as described in Saiki, et aL, Nature 324:163 (1986); U.S. Patent No. 4,683,195; and U.S. Patent No. 4,683,202. As used herein, x is "heterologous" with respect to y if x is not naturaUy associated with y in the identical manner; i.e., x is not associated with y in nature or x is not associated with y in the same manner as is found in nature. "Recombinant host ceUs," "host ceUs," "ceUs," "ceU Unes," "ceU cultures," and other such terms denoting mammaUan, insect, or microorganism ceUs that can be, or have been, used as recipients for a recombinant vector or other transfer DNA, and include the progeny of the original ceU which has been transformed. It is understood that the progeny of a single parental ceU may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deUberate mutation. SUBSTITUTE SHEET "MammaUan cells" are cells that are from a member of the Class Mammalia, and microorganism cells and insect cells are specifically excluded from this group. Insect cells and compatible vectors which are useful as recombinant expression systems are known in the art, and include, for example, insect expression and transfer vectors derived from the baculovirus Autographa calif omica nuclear polyhedrosis virus (hereinafter "AcNPV" or "baculovirus"), which is a helper-independent, viral expression vector. Viral expression vectors derived from this system usuaUy use the strong viral polyhedrin gene promoter to drive expression of heterologous genes. As used herein, the term "microorganism" includes prokaryotic and eukaryotic microbial species such as bacteria and fungi, the latter including yeast and filamentous fungi; the term "microorganism" specificaUy excludes mammaUan cells and insect cells. "Transformation," as used herein, refers to the insertion of an exogenous polynucleotide into a host ceU, irrespective of the method used for the insertion, for example, direct uptake, transfection, transduction, infection, or electroporation. The exogenous polynucleotide can be maintained as a non-integrated vector, for example, a plasmid, or alternatively, can be integrated into the host genome. "SubstantiaUy pure" as used herein means a level of purity which enables the practice of the appropriate function. With respect to PACE 4 or 4.1 polypeptides, these are in general substantiaUy pure if the levels of competing and interfering proteolytic enzymes are low enough to permit the activity of PACE 4 or 4.1 to generate the major reaction products. Preferably this means that the PACE 4 or 4.1 will account for at least 90% of the endoprotease activity, more preferably at least 95% of endoprotease activity, and most preferably at least 99% of endoprotease activity. As used herein, an "oUgonucleotide" is a polynucleotide containing from 10 to approximately 200 bases, usuaUy less than about 60 bases, and which is useful inter alia as a probe or diagnostic reagent for identifying the presence of a complementary nucleotide sequence. II. General modes for carrying out the invention The practice of the present invention wiU employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and SUBSTITUTE SHEET immunology, which are within the skiU of the art. Such techniques are explained fully in the Uterature. See e.g., Sambrook, et aL, MOLECULAR CLONING; A LABORATORY MANUAL, SECOND EDITION (1989); DNA CLONING, VOLUMES I AND II (D.N Glover ed. 1985); OLIGONUCLEOTIDE SYNTHESIS (M.J. Gait ed, 1984); NUCLEIC ACID HYBRIDIZATION (B.D. Hames & S.J. Higgins eds. 1984); TRANSCRIPTION AND TRANSLATION (B.D. Hames & S.J. Higgins eds. 1984); ANIMAL CELL CULTURE (R.I. Freshney ed. 1986); IM¬ MOBILIZED CELLS AND ENZYMES (IRL Press, 1986); B. Perbal, A PRACTICAL GUIDE TO MOLECULAR CLONING (1984); the series, METHODS IN ENZYMOLOGY (Academic Press, Inc.);' GENE TRANSFER VECTORS FOR MAMMALIAN CELLS (J.H. MiUer and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory), Methods in Enzymology Vol. 154 and Vol. 155 (Wu and Grossman, and Wu, eds., respectively), Mayer and Walker, eds. (1987), IMMUNOCHEMICAL METHODS IN CELL AND MOLECULAR BIOLOGY (Academic Press, London), Scopes, (1987), PROTEIN PURIFICATION: PRINCIPLES AND PRACTICE, Second Edition (Springer- Verlag, N.Y.), and HANDBOOK OF EXPERIMENTAL IM¬ MUNOLOGY, VOLUMES I-IV (D.M. Weir and C C BlackweU eds 1986). AU patents, patent appUcations, and pubUcations mentioned herein, both supra and infra, are hereby incorporated herein by reference. HI. Specific modes for carrying out the invention DNA sequences, constructs (vectors) containing the DNA sequences, and mammaUan, insect, and microorganism hosts containing these constructs are provided for herein. These compositions have utiUty in processes for producing PACE 4 and 4.1 and for producing mature polypeptides from heterologous precursor polypeptides. Also provided are compositions comprising substantiaUy pure PACE 4 or 4.1, and pharmaceutical compositions comprising PACE 4 or 4.1. AdditionaUy, methods for producing PACE 4 and 4.1, methods for inhibiting blood coagulation and for reducing blood pressure, and also methods for producing a desired mature polypeptide are included in the present invention. Methods for producing a desired mature polypeptide can include the foUowing techniques. First, a vector coding for both PACE 4 or 4.1 and the heterologous SUBSTITUTE SHEET precursor polypeptide can be inserted into a host cell, or two vectors coding, respectively, for PACE 4 or 4.1 and the heterologous precursor polypeptide, can be inserted into a host. Furthermore, two transformed hosts can be employed wherein one host expresses PACE 4 or 4.1 and the other host expresses the heterologous precursor polypeptide; these hosts can be co-cultured whereby PACE processes the heterologous precursor into the mature polypeptide in the medium. Another method employs a single transformed host ceU expressing PACE 4 or 4.1 , whereby PACE 4 or 4.1 is isolated from the cell and can be used in in vitro processing of a heterologous precursor polypeptide. The PACE 4 or 4.1 can be immobiUzed by, e.g., packing into or attaching to a column or other useful support configuration. Soluble or immobUized recombinant PACE 4 or 4.1 can be used as an added reagent to extracellular (or conditioned) media where a precursor product is secreted from the cell in which it is expressed. In some instances, it may be desirable to have a pluraUty of copies, two or more, of the gene expressing the expression product precursor in relation to the PACE 4 or 4.1 gene, or vice versa. This can be achieved in a variety of ways. For example, one can use separate vectors, where the vector having either PACE 4/4.1 or the heterologous precursor polypeptide has a higher copy number than the other vector. In this situation, it would be desirable to have different markers on the two vectors, so as to ensure the continued maintenance of the vectors in the mammalian host Alternatively, one could employ two transcriptional regulatory regions having different rates of transcriptional initiation, providing for enhanced expression of either the PACE 4 or 4.1 gene or the heterologous precursor polypeptide relative to the other gene. As another alternative, one can use different promoters, where one promoter provides for a low level of constitutive expression of either PACE or the heterologous precursor polypeptide, while the second promoter provides for a high level of induced expression of the other product. Examples of precursor polypeptides include, but are not timited to, transforming growth factor (TGF) beta and its superfamUy, including inhibin and activin; bone morphogenic proteins (BMP); insuUn and relaxin; coagulation factors, such as von Willebrand factor; growth factors, such as platelet derived growth factor (PDGF) and nerve growth factor (NGF); and virus polypeptides, including those from SUBSTITUTE SHEET cytomegalovirus (CMV), hepatitis delta virus (HDV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and herpes simplex virus (HSV). Any precursor polypeptide with at least one dibasic cleavage site is a candidate for this aspect of the present invention. The PACE 4 or 4.1 gene or a fragment thereof can be expressed in a mammaUan, insect, or microorganism host. The polynucleotide encoding PACE is inserted into a suitable expression vector compatible with the type of host ceU employed and is operably linked to the control elements within that vector. Vector construction employs techniques which are known in the art. Site-specific DNA cleavage involved in such construction is performed by treating with suitable restriction enzymes under conditions which generaUy are specified by the manufacturer of these commerciaUy avaUable enzymes. A suitable expression vector is one that is compatible with the desired function (e.g., transient expression, long term expression, integration, repUcation, amplification) and in which the control elements are compatible with the host ceU. Expression in mammaUan ceUs Vectors suitable for repUcation in mammaUan ceUs are known in the art, and can include viral repUcons, or sequences that ensure integration of the sequence encoding PACE into the host genome. Suitable vectors can include, for example, those derived from simian virus SV40, retroviruses, bovine papiUoma virus, vaccinia virus, and adenovirus. A suitable vector, for example, is one derived from vaccinia viruses. In this case, the heterologous DNA is inserted into the vaccinia genome. Techniques for the insertion of foreign DNA into the vaccinia virus genome are known in the art, and utitize, for example, homologous recombination. The insertion of the heterologous DNA is generaUy into a gene which is non-essential in nature, for example, the thymidine kinase gene (tk), which also provides a selectable marker. Plasmid shuttle vectors that greatly faciUtate the construction of recombinant viruses have been described (see, for example, Mackett et al. (1984), Chakrabarti et al. (1985); Moss (1987)). Expression of the heterologous polypeptide then occurs in ceUs or individuals which are immunized with the Uve recombinant vaccinia virus. SUBSTITUTE SHEET Such suitable mammaUan expression vectors usuaUy contain one or more eukaryotic transcription units that are capable of expression in mammalian cells. The transcription unit is comprised of at least a promoter element to mediate transcription of foreign DNA sequences. Suitable promoters for mammaUan cells are known in the art and include viral promters such as that from simian virus 40 (SV40), cytomegalovirus (CMV), Rous sarcoma virus (RSV), adenovirus (ADV), and bovine papilloma virus (BPV). The optional presence of an enhancer element (enhancer), combined with the promoter elements described above, will typicaUy increase expression levels. An enhancer is any regulatory DNA sequence that can stimulate transcription up to 1000- fold when linked to endogenous or heterologous promoters, with synthesis beginning at the normal mRNA start site. Enhancers are also active when they are placed upstream or downstream from the transcription initiation site, in either normal or flipped orien¬ tation, or at a distance of more than 1000 nucleotides from the promoter [Maniatis et al. (1987) Science 236:1237: Alberts et al. (1989) Molecular Biology of the Cell, 2nd ed.]. Enhancer elements derived from viruses may be particularly useful, because they typicaUy have a broader host range. Examples useful in mammaUan ceUs include the SV40 early gene enhancer [Dijkema et al (1985) EMBO J. 4:7611 and the enhancer/promoters derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus [Gorman et al. (1982b) Proc. Natl. Acad. Sci. 79:67771 and from human cytomegalovirus [Boshart et al. (1985) Cell 41:5211. Additionally, some enhancers are regulatable and become active only in the presence of an inducer, such as a hormone or metal ion [Sassone-Corsi and BoreUi (1986) Trends Genet. 2:215: Maniatis et al. (1987) Science 236:12371. In addition, the transcription unit can also be comprised of a termination ' sequence and poly(A) addition sequences which are operably linked to the PACE 4 or 4.1 coding sequence. The transcription unit can also be comprised of an enhancer sequence which increases the expression of PACE 4 or 4.1. Sequences that cause amplification of the gene may also be desirable, as are sequences which encode selectable markers. Selectable markers for mammaUan cells are known in the art, and include for example, thymidine kinase, dihydrofolate reductase (together with methotraxate as a DHFR amplifier), aminoglycoside SUBSTITUTE SHEET phosphotransferase, hygromycin B phosphotransferase, asparagine synthetase, adenosine deaminase, metaUothionien, and antibiotic resistant genes such as neomycin. The vector that encodes PACE can be used for transformation of a suitable mammaUan host ceU. Transformation can be by any known method for introducing polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus and transducing a host ceU with the virus or by tranfection procedures known in the art, as exemplified by U.S. Patent Nos. 4,399,216; 4,912,040; 4,740,461; 4,959,455 (these patents are incorporated herein by reference). The transformation procedure used depends upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammaUan ceUs are known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in Uposomes, and direct microinjection of the DNA into nuclei. MammaUan ceU lines ava able as hosts for expression are known in the art and include many immortalized ceU lines avaUable from the American Type Culture CoUection (ATCC), including but not limited to Chinese hamster ovary (CHO) ceUs, HeLa ceUs, baby hamster kidney (BHK) ceUs, monkey kidney ceUs (COS), human hepatoceUular carcinoma cells (e.g., Hep G2), and a number of other ceU lines. Expression in Insect CeUs In the case of expression in insect ceUs, generaUy the components of the expression system include a transfer vector, usuaUy a bacterial plasmid, which contains both a fragment of the baculovirus genome, and a convenient restriction site for insertion of the heterologous gene or genes to be expressed; a wUd type baculovirus with a sequence homologous to the baculovirus-specific fragment in the transfer vector (this aUows for the homologous recombination of the heterologous gene in to the baculovirus genome); and appropriate insect host ceUs and growth media. Currently, the most commonly used transfer vector for introducing foreign genes into AcNPV is pAc373. Many other vectors, known to those of skUl in the art, have also been designed. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and which introduces a BamHI cloning site SUBSTITUTE SHEET 32 basepairs downstream from the ATT; see Luckow and Summers, Virology (1989) 7:31. The plasmid usually also contains the polyhedrin polyadenylation signal (Miller et al. (1988) Ann. Rev. MicrobioL. 42:177) and a procaryotic ampicillin-resistance (amp) gene and origin of replication for selection and propagation in I coli. Baculovirus transfer vectors usuaUy contain a baculovirus promoter. A baculovirus promoter is any DNA sequence capable of binding a baculovirus RNA polymerase and initiating the downstream (5' to 3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region typically includes an RNA polymerase binding site and a transcription initiation site. A baculovirus transfer vector can also have a second domain caUed an enhancer, which, if present, is usuaUy distal to the structural gene. Expression can be either regulated or constitutive. Expression in Microorganisms Fungal expression systems can utiUze both yeast and filamentous fungi hosts. Examples of filamentous fungi expression systems are AspergiUus, as described in EPO Pub. No. 357 127 (pubUshed March 7, 1990), and Acremonium chrvsogenum, described in EPO Pub. No. 376 266 (pubUshed July 4, 1990). A yeast expression system can typically include one or more of the foUowing: a promoter sequence, fusion partner sequence, leader sequence, transcription termination sequence. These elements can be combined into an expression cassette, which can be maintained in a repUcon, preferably with a selectable marker. A yeast promoter is any DNA sequence capable of binding yeast RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter wiU have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region typicaUy includes an RNA polymerase binding site (the "TATA Box") and a transcription initiation site. A yeast promoter can also have a second domain caUed an upstream activator sequence (UAS), which, if present, is usually distal to the structural gene. The UAS permits regulated (inducible) SUBSTITUTE SHEET expression. Constitutive expression occurs in the absence of a UAS. Regulated expression can be either positive or negative, thereby either enhancing or reducing transcription. Yeast is a fermenting organism with an active metaboUc pathway, therefore sequences encoding enzymes in the metaboUc pathway provide particularly useful promoter sequences. Examples include alcohol dehydrogenase (ADH)(E.P.O. Pub. No. 284044), enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3- phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3- phosphoglycerate mutase, and pyruvate kinase (PyK)(E.P.O. Pub. No. 329203). The yeast PHO5 gene, encoding acid phosphatase, also provides useful promoter sequences [Myanohara et aL (1983) Proc. Natl. Acad. Sci. USA 80:11. In addition, synthetic promoters which do not occur in nature also function as yeast promoters. For example, UAS sequences of one yeast promoter can be joined with the transcription activation region of another yeast promoter, creating a synthetic hybrid promoter. Examples of such hybrid promoters include the ADH regulatory sequence Unked to the GAP transcription activation region (U.S. Patent Nos. 4,876,197 and 4,880,734). Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the ADH2, GAL4, GAL10, OR PHO5 genes, combined with the transcriptional activation region of a glycolytic enzyme gene such as GAP or PyK(E.P.O. Pub. No. 164556). Furthermore, a yeast promoter can include naturaUy occurring promoters of non-yeast origin that have the abiUty to bind yeast RNA polymerase and initiate transcription. Examples of such promoters include, inter aUa, [Cohen et al. (1980) Proc. Natl. Acad. Sci. USA 77:1078: Henikoff et al. (1981) Nature 283:835: HoUenberg et al. (1981) Curr. Topics Microbiol. Immunol. 96:119: HoUenberg et al. (1979) "The Expression of Bacterial Antibiotic Resistance Genes in the Yeast Saccharomyces cerevisiae," in: Plasmids of Medical, Environmental and Commercial Importance (eds. K.N. Timmis and A. Puhler); Mercerau-Puigalon et al. (1980) Gene 11:163: Panthier et al. (1980) Curr. Genet. 2:109:1. The PACE 4 gene or a fragment thereof can be expressed intraceUuIarly in yeast. A promoter sequence can be directly Unked with the PACE 4 gene or fragment, in which case the first amino acid at the N-terminus of the recombinant protein wiU always be a methionine, which is encoded by the ATG start codon. If desired, SUBSTITUTE SHEET methionine at the N-terminus can be cleaved from the protein by in vitro incubation with cyanogen bromide. IntraceUularly expressed fusion proteins provide an alternative to direct expression of the PACE gene or fragment. TypicaUy, a DNA sequence encoding the N-terminal portion of a stable protein, a fusion partner, is fused to the 5' end of heterologous DNA encoding the desired polypeptide. Upon expression, this construct wiU provide a fusion of the two amino acid sequences. For example, the yeast or human superoxide dismutase (SOD) gene, can be Unked at the 5' terminus of the PACE 4 gene or fragment thereof and expressed in yeast. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See e.g., E.P.O. Pub. No. 196056. Another example is a ubiquitin fusion protein. Such a ubiquitin fusion protein preferably retains a site for a processing enzyme (e.g. ubiquitin-specific processing protease) to cleave the ubiquitin from the PACE 4 or 4.1 polypeptide. Through this method, therefore, a mature PACE 4 or 4.1 polypeptide can be isolated (P.CT. WO 88/024066). Alternatively, PACE 4 or 4.1 polypeptides can also be secreted from the ceU into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion in yeast of the PACE 4 or 4.1 polypeptides. Preferably, there are processing sites encoded between the leader fragment and the PACE gene or fragment thereof that can be cleaved either in vivo or in vitro. The leader sequence fragment typicaUy encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the ceU. DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the yeast invertase gene (E.P.O. Pub. No. 12873; J.P.O. Pub. No. 62,096,086) and the A-factor gene (U.S. Patent No. 4,588,684). Alternatively, leaders of non-yeast origin, such as an interferon leader, exist that also provide for secretion in yeast (E.P.O. Pub. No. 60057). A preferred class of secretion leaders are those that employ a fragment of the yeast alpha-factor gene, which contains both a "pre" signal sequence, and a "pro" region. The types of alpha-factor fragments that can be employed include the full- length pre-pro alpha factor leader (about 83 amino acid residues) as well as truncated SUBSTITUTE SHEET alpha-factor leaders (typicaUy about 25 to about 50 amino acid residues) (U.S. Patent Nos. 4,546,083 and 4,870,008; E.P.O. Pub. No. 324274). Additional leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha-factor leaders made with a presequence of a first yeast, but a pro-region from a second yeast alphafactor. (See e.g., P.CT. WO 89/02463.) TypicaUy, transcription termination sequences recognized by yeast are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator sequence and other yeast-recognized termination sequences, such as those coding for glycolytic enzymes. TypicaUy, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs or cassettes are often maintained in a repUcon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as yeast or bacteria. The repUcon can have two repUcation systems, thus aUowing it to be maintained, for example, in yeast for expression and in a procaryotic host for cloning and amplification. Examples of such yeast-bacteria shuttle vectors include . YEp24 [Botstein et al. (1979) Gene 8:17-241, pCl/1 [Brake et aL (1984) Proc. Natl. Acad. Sci USA £l_:4642-4646], and YRpl7 [Stinchcomb et al. (1982) J. Mol. Biol. 158:1571. In addition, a repUcon can be either a high or low copy number plasmid. A high copy number plasmid wiU generaUy have a copy number ranging from about 5 to about 200, and typicaUy about 10 to about 150. A host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20. Either a high or low copy number vector may be selected, depending upon the effect on the host of the vector and the PACE polypeptides. See e.g., Brake et al., supra. Alternatively, the expression constructs can be integrated into the yeast genome with an integrating vector. Integrating vectors typicaUy contain at least one sequence homologous to a yeast chromosome that aUows the vector to integrate, and preferably contain two homologous sequences flanking the expression construct. Integrations appear to result from recombinations between homologous DNA in the vector and the SUBSTITUTE SHEET yeast chromosome [Orr- Weaver et al. (1983) Methods in Enzymol. 101:228-2451. An integrating vector can be directed to a specific locus in yeast by selecting the appropriate homologous sequence for inclusion in the vector. See Orr- Weaver et al., supra. One or more expression construct can integrate, possibly affecting levels of recombinant protein produced [Rine et al. (1983) Proc. Natl. Acad. Sci. USA 80:6750]. The chromosomal sequences included in the vector can occur either as a single segment in the vector, which results in the integration of the entire vector, or two segments homologous to adjacent segments in the chromosome and flanking the expression construct in the vector, which can result in the stable integration of only the expression construct. Typically, extrachromosomal and integrating expression vectors can contain selectable markers to allow for the selection of yeast strains that have been transformed. Selectable markers can include biosynthetic genes that can be expressed in the yeast host, such as ADE2, HIS4, LEU2. TRP1. and ALG7. and the G418 resistance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively. In addition, a suitable selectable marker can also provide yeast with the abiUty to grow in the presence of toxic compounds, such as metal. For example, the presence of CUP1 aUows yeast to grow in the presence of copper ions [Butt et al. (1987) Microbiol. Rev. 51:3511. Alternatively, some of the above described components can be put together into transformation vectors. Transformation vectors are typicaUy comprised of a selectable marker that is either maintained in a repUcon or developed into an integrating vector, as described above. Expression and transformation vectors, either extrachromosomal repUcons or integrating vectors, have been developed for transformation into many yeasts. For example, expression vectors have been developed for, inter alia, the following yeasts: Candida albicans [Kurtz, et al. (1986) Mol. Cell. Biol. 6.: 142], Candida maltosa [Kunze, et al. 91985) J. Basic Microbiol. 25.: 141]. Hansenula polvmorpha [Gleeson, et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302], Kluyveromyces fragilis [Das, et al. (1984) J. Bacteriol. 158:11651, Kluyveromyces lactis [De Louvencourt et al. (1983) J. Bacteriol. 154:737; Van den Berg et al. (1990) Bio/Technology 8.: 135], Pichia g llerimondii [Kunze et al. (1985) L SUBSTITUTE SHEET Basic Microbiol. 25:1411, Pichia pastoris [Cregg, et aL (1985) Mol. CeU. Biol. 5:3376: U.S. Patent Nos. 4,837,148 and 4,929,555], Saccharomyces cerevisiae [Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75:1929: Ito et al- 1983) J. Bacteriol. 153:1631, Schizosaccharomyces pombe [Beach and Nurse (1981) Nature 300:706], and Yarrowia Upolytica [Davidow, et al. (1985) Curr. Genet. 10:380471 GaUlardin, et aL (1985) Curr. Genet 10:491. Methods of introducing exogenous DNA into yeast hosts are weU-known in the art, and typicaUy include either the transformation of spheroplasts or of intact yeast ceUs treated with alkaU cations. Transformation procedures usuaUy vary with the yeast species to be transformed. See e.g., [Kurtz et al. (1986) Mol. CeU. Biol. 6:142; Kunze et al. (1985) J. Basic Microbiol. 25:141: Candida]; [Gleeson et al. (1986) J. Gen. Microbiol. 132:3459: Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302: Hansenulal: [Das et al. (1984) J. Bacteriol. 158:1165: De Louvencourt et al. (1983) Bacteriol. 154:1165: Van den Berg et aL (1990) Bio/Technology 8:135; Kluweromvcesl: [Cregg et aL (1985) Mol. CeU. Biol. 5:3376; Kunze et aL (1985) J. Basic Microbiol. 25:141; U.S. Patent Nos. 4,837,148 and 4,929,555, Pichia]; [Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75:1929: Ito et aL (1983) J. Bacteriol. 153:163 Saccharomvcesl: [Beach and Nurse (1981) Nature 300:706: Schizosaccharomycesl; [Davidow et al. (1985) Curr. Genet. 10:39; GaUlardin et al. (1985) Curr. Genet. .10:49; Yarrowial. AdditionaUy, the PACE 4 gene or a fragment thereof can be expressed in a bacterial system. Therein, a bacterial promoter is any DNA sequence capable of binding bacterial RNA polymerase and initiating the downstream (3") transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter wiU have a transcription initiation region which is usuaUy placed proximal to the 5' end of the coding sequence. This transcription initiation region typicaUy includes an RNA polymerase binding site and a transcription initiation site. A bacterial promoter can also have a second domain caUed an operator, that can overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein can bind the operator and thereby inhibit transcription of a specific gene. Constitutive expression can occur in the absence of negative regulatory elements, such as the operator. In SUBSTITUTE SHEET addition, positive regulation can be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5') to the RNA polymerase binding sequence. An example of a gene activator protein is the cataboUte activator protein (CAP), which helps initiate transcription of the lac operon in Escherichia coli (E. coli) [Raibaud et al. (1984) Annu. Rev. Genet. 18:1731. Regulated expression can therefore be either positive or negative, thereby either enhancing or reducing transcription. Sequences encoding metaboUc pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose (lac) [Chang et al. (1977) Nature 198:10561, and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (tip) [Goeddel et al. (1980) Nuc. Acids Res. 8:4057: Yelverton et al. (1981) Nucl. Acids Res. 9:731: U.S. Patent No. 4,738,921; E.P.O. Pub. Nos. 36,776 and 121,775]. The "-lactomase (bla) promoter system [Weissmann (1981) "The cloning of interferon and other mistakes." In Interferon 3 (ed. I. Gresser)], bacteriophage lambda PL [Shimatake et al. (1981) Nature 292:128] and T5 [U.S. Patent No. 4,689,406] promoter systems also provide useful promoter sequences. In addition, synthetic promoters which do not occur in nature also function as bacterial promoters. For example, transcription activation sequences of one bacterial or bacteriophage promoter can be joined with the operon sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter [U.S. Patent No. 4,551,433]. For example, the tac promoter is a hybrid trp-lac promoter comprised of both trrj promoter and tec operon sequences that is regulated by the lac repressor [Amann et aL (1983) Gene 25:167: de Boer et aL (1983) Proc. Natl. Acad. Sci. 80:211. Furthermore, a bacterial promoter can include naturally occurring promoters of non- bacterial origin that have the abUity to bind bacterial RNA polymerase and initiate transcription. A naturally occurring promoter of non- bacterial origin can also be coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes. The bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system [Studier et al. (1986) J. Mol. Biol. 189:113; Tabor et al. (1985) Proc Natl. Acad. Sci. 82:1074], In addition, a hybrid SUBSTITUTE SHEET promoter can also be comprised of a bacteriophage promoter and an I coli operator region (E.P.O. Pub. No. 267,851). In addition to a functioning promoter sequence, an efficient ribosome binding site is also useful for the expression of the PACE gene or fragment thereof in prokaryotes. In E_. coti, the ribosome binding site is caUed the Shine-Dalgarno (SD) sequence and includes an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon [Shine et al. (1975) Nature 254:341. The SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of bases between the SD sequence and the 3' and of E. coU 16S rRNA [Steitz et al. (1979) "Genetic signals and nucleotide sequences in messenger RNA." In Biological Regulation and Development: Gene Expression (ed. R.F. Goldberger)]. To express eukaryotic genes and prokaryotic genes with weak ribosome- binding site [Sambrook et al. (1989) "Expression of cloned genes in Escherichia coli." In Molecular Cloning: A Laboratory Manuall. PACE 4 or 4.1 can be expressed intraceUularly. A promoter sequence can be directly Unked with the PACE 4 gene or a fragment thereof, in which case the first amino acid at the N-terminus wiU always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus can be cleaved from the protein by in vitro incubation with cyanogen bromide or by either in vivo on in vitro incubation with a bacterial methionine N-terminal peptidase (E.P.O. Pub. No. 219,237). Fusion proteins provide an alternative to direct expression. TypicaUy, a DNA sequence encoding the N-terminal portion of an endogenous bacterial protein, or other stable protein, is fused to the 5' end of heterologous PACE 4 or 4.1 coding sequences. Upon expression, this construct wiU provide a fusion of the two amino acid sequences. For example, the bacteriophage lambda ceU gene can be Unked at the 5' terminus of the PACE gene or fragment thereof and expressed in bacteria. The resulting fusion protein preferably retains a site for a processing enzyme (factor Xa) to cleave the bacteriophage protein from the PACE gene or fragment thereof [Nagai et al. (1984) Nature 309:8101. Fusion proteins can also be made with sequences from the lacZ [Jia et aL (1987) Gene 60:197], ttpE [AUen et aL (1987) J. BiotechnoL 5:93; Makoff et al. (1989) J. Gen. Microbiol. 135:111, and Chev [E.P.O. Pub. No. 324,647] genes. The DNA sequence at the junction of the two amino acid sequences may or may not SUBSTITUTE SHEET encode a cleavable site. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin specific processing-protease) to cleave the ubiquitin from the PACE polypeptide. Through this method, mature PACE polypeptides can be isolated [Miller et al. ( 1989) Biotechnology 7:698]. Alternatively, PACE 4 or 4.1 polypeptides can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a signal peptide sequence fragment that provides for secretion of the PACE 4 or 4.1 polypeptides in bacteria [U.S. Patent No. 4,336,336]. The signal sequence fragment typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the ceU. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic spece, located between the inner and outer membrane of the ceU (gram-negative bacteria). Preferably there are processing sites, which can be cleaved either in vivo or in vitro encoded between the signal peptide fragment and the PACE 4 or 4.1 polypeptide. DNA encoding suitable signal sequences can be derived from genes for secreted bacterial proteins, such as the E. coU outer membrane protein gene (ompA) [Masui et al. (1983), in: Experimental Manipulation of Gene Expression; Ghrayeb et al. (1984) EMBO J. 3:24371 and the E. coli alkaline phosphatase signal sequence (phoA) [Oka et al. (1985) Proc. Natl. Acad. Sci. 82:72121. As an additional example, the signal sequence of the alpha-amylase gene from various BacUus strains can be used to secrete heterologous proteins from B. subtitis [Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; E.P.O. Pub. No. 244,042]. TypicaUy, transcription termination sequences recognized by bacteria are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Transcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structures that aid in terminating transcription. Examples include transcription termination sequences derived from genes with strong promoters, such as the trrj gene in E. coli as weU as other biosynthetic genes. SUBSTITUTE SHEET TypicaUy, the above described components, comprising a promoter, signal sequence (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a repUcon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host such as bacteria. The repUcon will have a repUcation system, thus aUowing it to be maintained in a procaryotic host either for expression or for cloning and amplification. In addition, a repUcon can be either a high or low copy number plasmid. A high copy number plasmid wiU generaUy have a copy number ranging from about 5 to about 200, and typicaUy about 10 to about 150. A host containing a high copy number plasmid wiU preferably contain at least about 10, and more preferably at least about 20 plasmids. Either a high or low copy number vector can be selected, depending upon the effect of the vector and the PACE 4 or 4.1 polypeptide on the host Alternatively, the expression constructs can be integrated into the bacterial genome with an integrating vector. Integrating vectors typicaUy contain at least one sequence homologous to the bacterial chromosome that aUows the vector to integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the bactedrial chromosome. For example, integrating vectors constructed with DNA from various Barillus strains integrate into the BacUlus chromosome (E.P.O. Pub. No. 127,328). Integrating vectors can also be comprised of bacteriophage or transposon sequences. TypicaUy, extrachromosomal and integrating expression constructs can contain selectable markers to aUow for the selection of bacterial strains that have been transformed. Selectable markers can be expressed in the bacterial host and can include genes which render bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline [Davies et al. (1978) Annu. Rev.Microbiol. 32:4691. Selectable markers can also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways. Alternatively, some of the above described components can be put together in transformation vectors. Transformation vectors are typicaUy comprised of a selectable marker that is either maintained in a repUcon or developed into an integrating vector, as described above. SUBSTITUTE SHEET Expression and transformation vectors, either extra-chromosomal replicons or integrating vectors, have been developed for transformation into many bacteria. For example, expression vectors have been developed for, inter alia, the following bacteria: Bacillus subtilis [Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; E.P.O. Pub. Nos. 36,259 and 63,953; P.CT. WO 84/04541], Escherichia coli [Shimatake et al. (1981) Nature 292:128; Amann et al. (1985) Gene 40:183; Studier et al. (1986) J. Mol. BioL 189:113; E.P.O. Pub. Nos. 36,776, 136,829 and 136,907; U.K. Patent Application Serial No. 8418273], Streptococcus cremoris [PoweU et al. (1988) Appl. Environ. Microbiol. 54:6551 Streptococcus lividans [PoweU et al. (1988) Appl. Environ. Microbiol. 54:6551. Streptomvces lividans [U.S. Patent No. 4,745,056]. Methods of introducing exogenous DNA into bacterial hosts are weU-known in the art, and typically include either the transformation of bacteria treated with CaCU or other agents, such as divalent cations and DMSO. DNA can also be introduced into bacterial ceUs by electroporation. Transformation procedures usuaUy vary with the bacterial species to be transformed. See e.g., [Masson et al. (1989) FEMS Microbiol. Lett 60:273; Palva et al. (1982) Proc. Nad. Acad. Sci. USA 79:5582: E.P.O. Pub. Nos. 36,259 and 63,953; P.CT. WO 84/04541, BaciUus], [MUler et al- (1988) Proc. Natl. Acad. Sci. 85:856: Wang et al. (1990) J. Bacteriol. 172:949, Campylobacterl, [Cohen et al. (1973) Proc. Natl. Acad. Sci. 69:2110; Dower et al. (1988) Nucleic Acids Res. J 6:6127; Kushner (1978) "An improved method for transformation of Escherichia coli with ColEl -derived plasmids. In Genetic Engineering: Proceedings of the International Symposium on Genetic Engineering (eds. H.W. Boyer and S. Nicosia); Mandel et al. (1970) J. Mol. Biol. 53:159: Taketo (1988) Biochim. Biophvs. Acta 949:318: Escherichial, [Chassy et al. (1987) FEMS Microbiol. Lett. 44:173 LactobaciUusl: [Fiedler et al. (1988) Anal. Biochem 170:38, Pseudomonasl: [Augustin et al. (1990) FEMS Microbiol. Lett. 66:203, Staphylococcusl, [Barany et al. (1980) J. Bacteriol. 144:698; Harlander (1987) "Transformation of Streptococcus lactis by electroporation," in: Streptococcal Genetics (ed. J. Ferretti and R. Curtiss IE); Perry et al. (1981) Infec. Immun. 32:1295: PoweU et al. (1988) Appl. Environ. Microbiol. 54:655: Somkuti et al. (1987) Proc. 4th Eyr. Cong. Biotechnology 1:412, Streptococcus!. SUBSTITUTE SHEET Expression and Detection of expressed PACE 4 or 4.1 In order to obtain PACE 4 or 4.1 expression, recombinant host ceUs derived from the transformants are incubated under conditions which aUow expression of the recombinant PACE encoding sequence. These conditions wiU vary, depending upon the host ceU selected. However, the conditions are readUy ascertainable to those of ordinary skiU in the art, based upon what is known in the art. Detection of PACE 4 or 4.1 expressed in the transformed host ceU can be accompUshed by several methods. For example, detection can be by enzymatic activity (or increased enzymatic activity or increased longevity of enzymatic activity) using fluorogenic substrates which are comprised of a dibasic cleavage site for which PACE is specific. PACE can also be detected by its immunological reactivity with anti-PACE antibodies. Therapeutic aspects of PACE 4 or 4.1 PACE 4 and 4.1 mRNAs are expressed at relatively high levels in the kidney, as demonstrated by northern blots (Figure 8). Since physiological conversion of prorenin to renin occurs in the kidney, PACE 4 and 4.1 are candidates for in vivo prorenin processing enzymes. Furthermore, PACE 4 and 4.1 convert prorenin to renin, a process which results in elevation of blood pressure. Blockers of PACE 4 and 4.1 enzymatic activity therefore limit blood pressure increase. PACE 4 and 4.1 inhibitors have therapeutic utitity in treating high blood pressure. PACE 4 and 4.1 appear likely to have physiological effects on endogenous proteins that possess dibasic cleavage sites. Any such effects can be exploited for therapeutic purposes. OUgonucleotide probes Probes based upon the PACE 4 gene sequence or its complementary sequence are useful for detecting the presence of nucleotide sequences encoding PACE 4 or related polypeptides. Such probes can be used for example to detect PACE 4 mRNA transcription in tissues, or to identify the PACE 4 encoding bands on gels, or to identify structuraUy related homologous proteins. Since PACE 4 and 4.1 are known to share regions of homology with other dibasic cleaving endoproteases such as KEX2, PC1/PC3, PC2, and furin/PACE, probes based upon regions of the PACE 4 sequence SUBSTITUTE SHEET which are not shared with these other endoproteases are especially useful in discriminating PACE 4 related sequences from the other endoproteases. A comparison of the amino acid sequence of PACE 4 with these other endoproteases is given in Figure 7. Within the catalytic domain, the regions from amino acids 164 to 168, 172 to 189, 239 to 243, and 397 to 404 are seen to be unique to PACE 4. Other unique sequences exist in the noncatalytic domain of PACE 4 and 4.1. PACE 4 contains a large cysteine-rich region (CRR) within its C-terminal region which is unique to this protease, although a smaUer CRR exists within furin/PACE. PACE 4 and 4.1 also have extended signal peptide sequences, compared to the other proteases in the famUy. In addition, PACE 4 and 4.1 have neither the classical transmembrane anchor domain of furin/PACE, nor the amphipathic helix (AH) surface membrane anchor proposed for PC 2 and PC1/PC3. Thus significant sequence differences from other PACE family proteases exist in the noncatalytic domains of PACE 4 and 4.1. Probes based upon the nucleotide sequences corresponding to the above unique amino acid sequences are expected to be selective for PACE 4 and 4.1 and previously unknown homologues. A probe based on at least 15, and more preferably at least 20 consecutive nucleotides from the unique PACE 4 sequences and optionally in part upon the common endoprotease conserved regions, or alternatively the simultaneous or consecutive use of two probes based upon the unique and conserved regions respectively, permits identification of PACE 4 related endoproteases which are distinct from those identifiable by probes based only on sequences shared by PACE 4 and the known related protease sequences of Figure 7. In tight of the present disclosure, numerous embodiments within the scope of the claims will be apparent to those of ordinary skill in the art The foUowing experimental section is intended to be merely iUustrative and does not limit the present scope in any way. SUBSTITUTE SHEET Example 1 PCR Identification of PACE 4 + cDNA Clones To identify and clone new members of the human subtiUsin-Uke protease gene famUy, degenerate PCR primers were designed and synthesized corresponding to stretches of amino acids in the highly conserved catalytic domains of yeast KEX2 (SEQ ID NO: 7), human PACE (SEQ ID NO: 8), human PC2 (SEQ ID NO: 9), and mouse PC1/PC3 (SEQ ID NO: 10). These included regions containing the active site Asp (DDGI) and the active site His (HGTRC). OUgonucleotide synthesis OUgonucleotide adaptors, probes, and primers were synthesized as previously described (Kiefer et al., 1991). The two consensus PCR primers used to identify PACE 4 (SEQ ID NO: 1) were a sense primer consisting of a mixture of 16 23-mers (S'-AGATCTGAATTCGA^/^GA^/^GGXAT-S') (SEQ ID NO: 12) and an antisense primer consisting of a mixture of 64 27-mers (5'-AGATCTAAGCTTACAC- C( G / T) XGTXCC( A / G) TG-3') (SEQ ED NO: 13), where X denotes aU four deoxynucleotides. The PACE 4 probes used to screen the Ost4 cDNA Ubrary were a 24mer, (5'-TATTCATTGCCGTTCACGTCGTAG-3') (SEQ ID NO: 14) and a 22mer (5'-GCTGGCATCATATCGTGGAGAT-3') (SEQ ID NO: 15) that were derived from the sequence complementary to the PACE 4 PCR product (see below). Polymerase chain reactions (PCR) PCR was performed as described (Sa et aL, 1985) with modifications (Kiefer et al., 1991). The reactions were performed using the PCR primers described above at 8 mM and human osteosarcoma, Uver or kidney (293) cDNA at 0.1-1 ng/ml. PCR products migrating between 120-170 base pairs on a 7% acrylamide gel were excised, subcloned into Ml 3 and sequenced. Construction and screening of cDNA and genomic DNA Ubraries A 293 cDNA Ubrary was constructed in ZAPII as described by Zapf et 7 (1990). 6 x 10 independent recombinant clones were obtained. The HepG2 cDNA Ubrary (Zapf et aL, 1990) and the human osteosarcoma (Ost4) cDNA Ubrary (Kiefer et SUBSTITUTE SHEET al., 1991) have been described previously. An oriented cDNA Ubrary was constructed in the yeast expression vector pAB23BXN using poly (A) + mRNA isolated from the human liver cell line HEPG2. pAB23BXN is a derivative of pAB23BX (D. Schild et al. (1990), Proc. Natl. Acad. Sci. USA 87:2916) into which a synthetic polylinker, that contained Bst XI and Not 1 sites, was inserted for unidirectional cDNA cloning. Approximately 300,000 recombinant phage from the Ost4 Ubrary were screened as described (Kiefer et al., 1991) using the two PACE 4 oUgonucleotide probes. The HepG2 and 293 cDNA libraries were plated as above and screened with a =1.0 Kb Bglϋ DNA fragment derived from the 5' end of the Ost 4 cDNA clone, Os-1. The 293 cDNA Ubrary was subsequently further screened with a =500 bp EcoRI fragment derived from the 3' end of the 293 cDNA clone, K-15, and a synthetic oligonucleotide (PACE2.115) derived from a sequence complementary to the 5' end of PACE 4 cDNA (SEQ ID NO: 1) and including the initiation codon (5'-GGAGGCATAGCGGCGAC-3') (SEQ ID NO: 16). The cDNA probes were labeled as described (Feinberg and Vogelstein, 1984) and were hybridized to filters under conditions described above for the oUgonucleotide probes except that the hybridization solution contained 40% formamide. The filters were washed twice for 20 min,. in 0.2 x SSC, 0.1% SDS at 65°C To obtain the human PACE 4 gene (SEQ ID NO: 1), 600,000 colonies from a human genomic DNA Ubrary cloned in the cosmid vector pWE15 (Stratagene, San Diego, CA) were plated and screened with a =1.0 Kb BgHI DNA fragment from the 5' end of the Os-1 cDNA clone and subsequently with a =1.1 kb EcoRI DNA fragment from the 3' end of the L2-1 cDNA clone (Fig. 4). Two overlapping clones of =35-40 kb were obtained which hydridized to the 5' probe (PACE4-COS 3) and 3' probe (PACE4-COS 8.1). Plasmid and cosmid isolation, subcloning and DNA sequencing Standard procedures for the isolation and manipulation of DNA are from Sambrook et al. (1989). Plasmid DNA was propagated in E. coli strains HB101, D1210 or XL-1 Blue (Stratagene). DNA sequencing was performed by the dideoxy ^hain termination method (Sanger et al., 1977) using M13 primers as weU as specific SUBSTITUTE SHEET internal primers. Ambiguous regions were resolved using 7-deaza-2'-deoxyguanosine- 5'- triphosphate (Barr et al., 1986) and Sequenase (U.S. Biochemicals). After PCR amplification of cDNA reverse transcribed from poly(A) + RNA isolated from human ceU lines HEPG2 and 293 and from human osteosarcoma ceUs, the expected products (circa 150 base pairs) were gel purified, pooled and subcloned into the M13 mpl8 DNA sequencing vector. Sequence analysis of 10 PCR products revealed one sequence that was predicted to encode a stretch of 37 aminό acids displaying 30-60% sequence identity to yeast KEX2 (SEQ ID NO: 7), human furin/PACE (SEQ ID NO: 8), human PC2 (SEQ ID NO: 9) and mouse PC1/PC3 (SEQ ID NO: 10). In an attempt to isolate a fuU length cDNA encoding the new human subtiUsin- like protease, an osteosarcoma (Ost4) cDNA Ubrary was screened with an oUgonucleotide probe derived from the sequence of the 37 amino acid encoding PCR product. One clone (Os-1 ) was identified, among 300,000 recombinant plaques screened, and was found to contain a 3.6 kUobase (kb) cDNA insert (Fig. 4). Comparison of the deduced amino acid sequence of this clone with the sequence of furin/PACE (SEQ ID NO: 8) revealed that it was missing approximately 200 amino acids from the amino-terminus. Molecular cloning of PACE 4 (SEQ ID NO: 1) and 4.1 (SEQ ID NO: 1) and (SEQ ID NO: 3) cDNAs and PACE 4 gene (SEQ ID NO: 1) Subsequently, 300,000 recombinant plaques from a HepG2 cDNA Ubrary were probed with a 1.0 kb Bgiπ DNA fragment derived from the 5' end of the Os-1 cDNA clone. This resulted in the isolation of two approximately fuU length clones with DNA inserts of 4.4 kb (clone L2-1 ) and 4.3 kb (clone L2-10). Preliminary Northern blot analysis of several tissues and ceU lines using the 1.0 kb Os-1 DNA probe identified a 4.4 kb mRNA transcript in most tissues (described below). In addition, the kidney ceU line 293 revealed a mRNA of approximately 2.0 kb. The size of this transcript suggested that an alternative form of the PACE 4 protein (SEQ ID NO: 2) existed since the mRNA size required to encode PACE 4 is 2.9 kb (Fig. 1) (SEQ ID NO: 1). In an attempt to isolate this PACE 4 variant cDNA, SUBSTITUTE SHEET termed PACE 4.1 (SEQ ID NO: 1) and (SEQ ID NO: 3), a 293 cDNA library was constructed and 300,000 recombinant plaques were screened with the 1.0 kb Os-1 DNA probe. Several positive clones were identified including one that contained a cDNA insert of 1.7 kb (clone K-15). Preliminary DNA sequence analysis revealed that it was identical to PACE 4 (SEQ ID NO: 1) at the 5' end but was lacking 270bp encoding the amino-terminal 90 amino acids. DNA sequence analysis also revealed a unique 3' end on PACE 4.1 (SEQ ID NO: 1) and (SEQ ID NO: 3) that was contained almost entirely on a 0.5kb EcoRI DNA fragment (Fig. 5). Therefore, this unique PACE 4.1 EcoRI DNA fragment and an oUgonucleotide probe complementary to the 5' end of PACE 4 were used to rescreen the 293 cDNA Ubrary. One clone was identified (K-l.l) that hybridized to both probes and was shown to contain a fuU-length cDNA insert of 1.9 kb. Example 2 Structures of PACE 4 (SEO ID NO: 1) and 4.1 (SEO ID NO: 1) and (SEO ID NO: 3) deduced from cDNA sequences The fuU sequence of the PACE 4 cDNA and the encoded protein sequence (SEQ ID NO: 1) are shown in Figure 1. The encoded protein sequence is shown above that of the cDNA sequence; the numbering is based on the significant ORF in the cDNA. Likely active site residues are indicated by asterisks. Consensus sites for Asn-linked glycosylation are marked by diamonds and cysteine residues by bars. Potential dibasic proteolytic processing sites are indicated by arrows. The coding sequence of PACE 4 (SEQ ID NO: 1) contains three consensus sites for N-linked glycosylation and fifty-six cysteine residues. The active site, shown in the box in Figure 1, includes a triad of amino acids: aspartate (Asp 205), histidine (His 246), and serine (Ser 420). A cysteine-rich region (CRR) is also present and, as shown in Figure 1, is located in the vicinity of amino acid Cys 695 to amino acid Cys 965. The translation of PACE 4 (SEQ ID NO: 1) is most likely initiated at the ATG start codon shown (Fig. 1), since this is the only in-frame Met codon in the 5' region of the cDNA. In contrast to the amino-terminal sequence of furin/PACE (SEQ ID NO: 8), this Met is not followed immediately by a classical hydrophobic signal sequence. SUBSTITUTE SHEET However, amino acids 43-63 of the large open reading frame resemble closely the proposed signal sequence for furin/PACE (Barr et aL, 1991) (SEQ ID NO: 8), including a predicted signal peptidase cleavage site foUowing Ala63 (Fig. 1, arrowed) (von Heijne, 1986). The open reading frame encodes a PACE 4 precursor protein of 5 969 amino acids (SEQ ID NO: 1) with a calculated molecular weight of 106.4 kD. As with KEX2 (SEQ ID NO: 7) and its mammaUan counterparts, PACE 4 (SEQ ID NO: 1) contains a region of clustered basic residues immediately preceding the catalytic domain (Fig 1). By direct comparison with the known cleavage sites for KEX2 (SEQ ED NO: 7), PC2 (SEQ ID NO: 9) and PC1/PC3 (SEQ ID NO: 10) (Christie et aL, 10 1991; Shennan et aL, 1991) the Arg-Val-Lys-Arg motif at amino acids 146-149 most likely represents a propeptide cleavage junction, thereby making Gin 150 the likely amino terminus of mature PACE 4 (SEQ ID NO: 1). The inferred sequence of PACE 4 (SEQ ID NO: 1) contains three consensus sites for N-linked glycosylation and 56 Cys residues, with 44 of these Cys residues 15 clustered in a carboxyl-terminal Cys-rich region analogous to, although somewhat longer than, that of furin/PACE (SEQ ID NO: 8). Again, in contrast to furin/PACE (SEQ ID NO: 8), which has a classical transmembrane domain, PACE 4 (SEQ ID NO: 1) does not appear to possess such a region of hydrophobic amino acid residues for anchorage in ceU membranes. Moreover, PACE 4 (SEQ ID NO: 1) does not have a 20 carboxyl-terminal amphipathic helix type anchor sequence proposed for PC2 (SEQ ID NO: 9) and PC1/PC3 (SEQ ID NO: 10) (Smeekens et aL, 1991) and carboxypeptidase E (Flicker et al., 1990), thereby suggesting an alternate mode of subceUular locaUzation for this enzyme. The PACE 4.1 cDNA (SEQ ID NO: 1) and (SEQ ID NO: 3), isolated from the 25 human kidney ceU line, encodes a much smaUer subtiUsin-Uke protease with a termination codon introduced immediately subsequent to the catalytic domain and leading to a calculated molecular weight for PACE 4.1 (SEQ ID NO: 1) and (SEQ ID NO: 3) of 53.3 kD (Figs. 2B, 3). Truncation at this point removes a region of the molecule referred to as the P-domain. This region is siimlar to one which was 30 identified in KEX2 (SEQ ID NO: 7), and which has been shown to be essential for the activity of the yeast protease. The PACE 4.1 cDNA (SEQ ID NO: 1) and (SEQ ED NO: 3) also contains a 3-untranslated region that is distinct from that of PACE 4 (SEQ SUBSTITUTE SHEET ID NO: 1) (Fig. 2) (SEQ ID NO: 3), but is encoded by the 5'-cosmid clone PACE4- COS 3. That alternate RNA splicing is occurring in this region can be inferred from the sequences of genomic clones isolated from this cosmid. For example, the sequence of a 620bp Pstl fragment from this cosmid encodes an exon (equivalent to exon 12 of furin/PACE (SEQ ID NO: 5)) that clearly iUustrates the intron/exon spUce junction leading to either PACE 4 (SEQ ED NO: 1) or PACE 4.1 (SEQ ID NO: 1) and (SEQ ID NO: 3) (Fig. 3) (SEQ ID NO: 5). The unique CRR of PACE 4 (SEQ ID NO: 1) comprises the C-terminal portion of the protein, including 44 cystine residues occurring between Cys695 and Cys965. The CRR apparently provides for localized interactions between PACE 4 (SEQ ID NO: 1) and other ceUular components, thereby modifying the activity of the enzyme. The CRR domain is used to create novel fusion proteins by combining an oligonucleotide encoding the CRR with one encoding a functional domain of a heterologous protein. For example, a fusion protein having the catalytic domain of a different endoprotease and the CRR of PACE 4 (SEQ ID NO: 1) is constructed by joining the appropriate DNA sequence coding for the endoprotease catalytic domain in reading frame with a DNA sequence encoding the CRR, and operatively inserted into an expression vector. The catalytic domain of PC2 (SEQ ED NO: 9) provides proteolytic activity having altered specificity from that of natural PACE 4 (SEQ ID NO: 1). DNA encoding PC2 (SEQ ED NO: 9) is cleaved at a site 5' to the start codon and a site 3' to the region encoding the catalytic domain. PACE 4 clone L2-10 is cleaved with BglΗ and the C-terminal fragment including the CRR is isolated and Ugated to the N-terminal DNA fragment from PC2. This construct is Ugated into an expression vector. Expression of the construct in transformed ceUs yields a novel endoprotease having catalytic characteristics of PC2 and the ceUular interactions of PACE 4. Example 3 Similarity of PACE 4 to other dibasic endoproteases Comparisons of the sequence and structure of PACE 4 (SEQ ID NO: 11) and PACE 4.1 (SEQ ID NO: 11) with KEX2 (SEQ ID NO: 7) and its mammalian homologs are illustrated in Figs. 6 and 7. In addition to the conservation of spacing of SUBSTITUTE SHEET the catalytic Asp, His, Asn (Asp), and Ser residues, also clearly apparent is the simUarity in placement of the proposed processing site for removal of the propeptide region of each protease (Fig. 6). That this cleavage site is utiUzed has been demonstrated for KEX2 (SEQ ID NO: 7) and for PC2 (SEQ ID NO: 9) and PC1/PC3 (SEQ ED NO: 10) (Christie et al., 1991; Shennan et aL, 1991). Amino acid sequence identities between the catalytic domain of PACE 4 (SEQ ID NO: 11) and those of the previously described dibasic processing enzymes are shown in Fig. 7, and quantitated in Table 1. TABLE 1. OVERALL % AMINO ACID SEQUENCE IDENTITIES BETWEEN THE CATALYTIC DOMAINS OF SACCHAROMYCES CEREVISIAE KEX2, AND THE MAMMALIAN PAIRED BASIC AMINO ACID RESIDUE CLEAVING ENZYMES yKEX2 furin/PACE PC2 PC1/PC3 PACE4 yKEX2 (SEQ ID NO: 7) furin/PACE 48 (SEQ ID NO: 8) PC2 47 56 (SEQ ID NO: 9) PC1/PC3 49 65 57 (SEQ ID NO: 10) PACE4 45 69 53 63 (SEQ ID NO: 11) SUBSTITUTE SHEET Example 4 Tissue distribution of PACE 4 mRNA To determine the tissue distribution of PACE 4 (SEQ ID NO: 1) and PACE 4.1 (SEQ ID NO: 1) and (SEQ ID NO: 3), northern blot analysis of poly(A)+ RNA from a variety of tissues and cell lines was carried out using cDNA probes specific to each transcript (Fig. 8 A-D). Northern blot analysis Multiple tissue Northern (MTN) blots (panels A and B, Figure 8) containing poly(A)+ RNA (2 μg) from human heart (lane 1), brain (lane 2), placenta (lane 3), lung (lane 4), Uver (lane 5), skeletal muscle (lane 6), kidney (lane 7) and pancreas (lane 8) were purchased from Clontech (Palo Alto, CA). Poly(A)+ RNA (2 μg) (panels C and D) from hamster insulinoma cell line HIT- 15 (lane 9), human embryonic kidney cell line 293 (lane 10), human hepatoma ceU Une HEP G2 (lane 11), human umbitical vein endotheUal ceUs (lane 12), human monocyte ceU Une U937 (lane 13), human lymphoblastoid cell line UC-729-6 (lane 14), and human osteosarcoma tissue (lane 15) were fractionated on 1.4% agarose gels in the presence of formaldehyde (Lehrach et al., 1977) transferred directly to nitroceUulose and processed as described (Thomas, 1980). Blots were hybridized with a PACE 4 specific probe (panels A and C) or a PACE 4.1 specific probe (panels B and D). Hybridization and washing conditions were as described above for the screening of cDNA Ubraries using cDNA probes. A single PACE 4 4.4 kb transcript was seen at various levels in all tissues and cell lines tested (Fig. 8 A and C). This is simUar to the widespread tissue distribution found with furin PACE (Schalken et aL, 1987; Ban * et al., 1991) and is in contrast to the limited neuroendocrine tissue distribution of PC2 and PC3 transcripts (Smeekens and Steiner, 1990; Seidah et al., 1990; Smeekens et al., 1991). However, the 2.0 kb PACE 4.1 transcript was seen only in the 293 kidney ceU Une from which it was originally isolated (Fig. 8 B and D). The lack of the 2.0 kb PACE 4.1 transcript in all tissues tested suggests that it may represent an alternatively spUced PACE 4 transcript limited to certain ceU types. SUBSTITUTE SHEET IV. Deposit of biological material Escherichia coti strain KB 101 host ceUs transformed with pAB23BXN-PACE 4 was deposited on October 11, 1991, with the American Type Culture CoUection (ATCC), RockviUe, MD, and designated as pAB23BXN-PACE 4 in E. coli. This deposit wiU be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for purposes of patent procedure. The accession number is avaUable from the ATCC This deposit is provided merely as convenience to those of skiU in the art, and is not an admission that a deposit is required under 35 U.S.C § 112. The nucleic acid sequence of this plasmid, as weU as the amino acid sequence of the polypeptide encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with the description herein. A Ucense may be required to make, use, or seU the deposited material, and no such Ucense is hereby granted. AU publications and patent appUcations mentioned in this specification are herein incorporated by reference to the same extent as if each individual pubUcation or patent appUcation was specificaUy and individuaUy indicated to be incorporated by reference. The invention now being fully described, it wiU be apparent to one of ordinary skiU in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims. SUBSTITUTE SHEET SEQUENCE LISTING GENERAL INFORMATION: (i) APPLICANT: BARR, PHILIP J KIEFER, MICHAEL C (ii) TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR PACE 4 AND PACE 4.1 GENE AND POLYPEPTIDES IN CELLS (iii) NUMBER OF SEQUENCES: 16 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: COOLEY GODWARD CASTRO HUDDLESON & TATUM (B) STREET: FIVE PALO ALTO SQUARE (C) CITY: PALO ALTO (D) STATE: CALIFORNIA ' (E) COUNTRY: USA (F) ZIP: 94306 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: US 07/848,629 (B) FILING DATE: 09-MAR-1992 (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: NEELEY PH.D., RICHARD L (B) REGISTRATION NUMBER: 30092 (C) REFERENCE/DOCKET NUMBER: CHIR-009/00US (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (415) 494-7622 (B) TELEFAX: (415) 857-0663 (C) TELEX: 380816 COOLEY PA (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4403 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (cDNA) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 170..3077 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: SUBSTITUTE SHEET CGGGAACGCG CCGCGGCCGC CTCCTCCTCC CCGGCTCCCG CCCGCGGCGG TGTTGGCGGC 60 GGCGGTGGCG GCGGCGGCGG CGCTTCCCCG GCGCGGAGCG GCTTTAAAAG GCGGCACTCC 120 ACCCCCCGGC GCACTCGCAG CTCGGGCGCC GCGCGAGCCT GTCGCCGCT ATG CCT 175 Met Pro 1 CCG CGC GCG CCG CCT GCG CCC GGG CCC CGG CCG CCG CCC CGG GCC GCC 223 Pro Arg Ala Pro Pro Ala Pro Gly Pro Arg Pro Pro Pro Arg Ala Ala 5 10 15 GCC GCC ACC GAC ACC GCC GCG GGC GCG GGG GGC GCG GGG GGC GCG GGG 271 Ala Ala Thr Asp Thr Ala Ala Gly Ala Gly Gly Ala Gly Gly Ala Gly 20 - 25 30 GGC GCC GGC GGG CCC GGG TTC CGG CCG CTC GCG CCG CGT CCC TGG CGC 319 Gly Ala Gly Gly Pro Gly Phe Arg Pro Leu Ala Pro Arg Pro Trp Arg 35 40 45 50 TGG CTG CTG CTG CTG GCG CTG CCT GCC GCC TGC TCC GCG CCC CCG CCG 367 Trp Leu Leu Leu Leu Ala Leu Pro Ala Ala Cys Ser Ala Pro Pro Pro 55 60 65 CGC CCC GTC TAC ACC AAC CAC TGG GCG GTG CAA GTG CTG GGC GGC CCG 415 Arg Pro Val Tyr Thr Asn His Trp Ala Val Gin Val Leu Gly Gly Pro 70 75 80 GCC GAG GCG GAC CGC GTG GCG GCG GCG CAC GGC TAC CTC AAC TTG GGC 463 Ala Glu Ala Asp Arg Val Ala Ala Ala His Gly Tyr Leu Asn Leu Gly 85 90 95 CAG ATT GGA AAC CTG GAA GAT TAC TAC CAT T T TAT CAC AGC AAA ACC 511 Gin lie Gly Asn Leu Glu Asp Tyr Tyr His Phe Tyr His Ser Lys Thr 100 105 110 TTT AAA AGA TCA ACC TTG AGT AGC AGA GGC CCT CAC ACC TTC CTC AGA 559 Phe Lys Arg Ser Thr Leu Ser Ser Arg Gly Pro His Thr Phe Leu Arg 115 120 125 130 ATG GAC CCC CAG GTG AAA TGG CTC CAG CAA CAG GAA GTG AAA CGA AGG 607 Met Asp Pro Gin Val Lys Trp Leu Gin Gin Gin Glu Val Lys Arg Arg 135 140 145 GTG AAG AGA CAG GTG CGA AGT GAC CCG CAG GCC CTT TAC TTC AAC GAC 655 Val Lys Arg Gin Val Arg Ser Asp Pro Gin Ala Leu Tyr Phe Asn Asp 150 155 160 CCC ATT TGG TCC AAC ATG TGG TAC CTG CAT TGT GGC GAC AAG AAC AGT 703 Pro lie Trp Ser Asn Met Trp Tyr Leu His Cys Gly Asp Lys Asn Ser 165 170 175 CGC TGC CGG TCG GAA ATG AAT GTC CAG GCA GCG TGG AAG AGG GGC TAC 751 Arg Cys Arg Ser Glu Met Asn Val Gin Ala Ala Trp Lys Arg Gly Tyr 180 185 190 ACA GGA AAA AAC GTG GTG GTC ACC ATC CTT GAT GAT GGC ATA GAG AGA 799 Thr Gly Lys Asn Val Val Val Thr lie Leu Asp Asp Gly lie Glu Arg 195 200 205 210 SUBSTITUTE SHEET AAT CAC CCT GAC CTG GCC CCA AAT TAT GAT TCC TAC GCC AGC TAC GAC 847 Asn His Pro Asp Leu Ala Pro Asn Tyr Asp Ser Tyr Ala Ser Tyr Asp 215 220 225 GTG AAC GGC AAT GAT TAT GAC CCA TCT CCA CGA TAT GAT GCC AGC AAT 895 Val Asn Gly Asn Asp Tyr Asp Pro Ser Pro Arg Tyr Asp Ala Ser Asn 230 235 240 GAA AAT AAA CAC GGC ACT CGT TGT GCG GGA GAA GTT GCT GCT TCA GCA 943 Glu Asn Lys His Gly Thr Arg Cys Ala Gly Glu Val Ala Ala Ser Ala 245 250 255 AAC AAT TCC TAC TGC ATC GTG GGC ATA GCG TAC AAT GCC AAA ATA GGA 991 Asn Asn Ser Tyr Cys lie Val Gly lie Ala Tyr Asn Ala Lys lie Gly 260 265 270 GGC ATC CGC ATG CTG GAC GGC GAT GTC ACA GAT GTG GTC GAG GCA AAG 1039 Gly lie Arg Met Leu Asp Gly Asp Val Thr Asp Val Val Glu Ala Lys 275 280 285 290 TCG CTG GGC ATC AGA CCC AAC TAC ATC GAC ATT TAC AGT GCC AGC TGG 1087 Ser Leu Gly lie Arg Pro Asn Tyr lie Asp lie Tyr Ser Ala Ser Trp 295 300 305 GGG CCG GAC GAC GAC GGC AAG ACG GTG GAC GGG CCC GGC CGA CTG GCT 1135 Gly Pro Asp Asp Asp Gly Lys Thr Val Asp Gly Pro Gly Arg Leu Ala 310 315 320 AAG CAG GCT TTC GAG TAT GGC ATT AAA AAG GGC CGG CAG GGC CTG GGC 1183 Lys Gin Ala Phe Glu Tyr Gly lie Lys Lys Gly Arg Gin Gly Leu Gly 325 330 335 TCC ATT TTC GTC TGG GCA TCT GGG AAT GGC GGG AGA GAG GGG GAC TAC 1231 Ser lie Phe Val Trp Ala Ser Gly Asn Gly Gly Arg Glu Gly Asp Tyr 340 345 350 TGC TCG TGC GAT GGC TAC ACC AAC AGC ATC TAC ACC ATC TCC GTC AGC 1279 Cys Ser Cys Asp Gly Tyr Thr Asn Ser He Tyr Thr He Ser Val Ser 355 360 365 370 AGC GCC ACC GAG AAT GGC TAC AAG CCC TGG TAC CTG GAA GAG TGT GCC 1327 Ser Ala Thr Glu Asn Gly Tyr Lys Pro Trp Tyr Leu Glu Glu Cys Ala 375 380 385 TCC ACC CTG GCC ACC ACC TAC AGC AGT GGG GCC TTT TAT GAG CGA AAA 1375 Ser Thr Leu Ala Thr Thr Tyr Ser Ser Gly Ala Phe Tyr Glu Arg Lys 390 395 400 ATC GTC ACC ACG GAT CTG CGT CAG CGC TGT ACC GAT GGC CAC ACT GGG 1423 He Val Thr Thr Asp Leu Arg Gin Arg Cys Thr Asp Gly His Thr Gly 405 410 415 ACC TCA GTC TCT GCC CCC ATG GTG GCG GGC ATC ATC GCC TTG GCT CTA 1471 Thr Ser Val Ser Ala Pro Met Val Ala Gly He He Ala Leu Ala Leu 420 425 430 GAA GCA AAC AGC CAG TTA ACC TGG AGG GAC GTC CAG CAC CTG CTA GTG 1519 Glu Ala Asn Ser Gin Leu Thr Trp Arg Asp Val Gin His Leu Leu Val 435 440 445 450 SUBSTITUTE SHEET AAG ACA TCC CGG CCG GCC CAC CTG AAA GCG AGC GAC TGG AAA GTA AAC 1567 Lys Thr Ser Arg Pro Ala His Leu Lys Ala Ser Asp Trp Lys Val Asn 455 460 465 GGC GCG GGT CAT AAA GTT AGC CAT TTC TAT GGA TTT GGT TTG GTG GAC 1615 Gly Ala Gly His Lys Val Ser His Phe Tyr Gly Phe Gly Leu Val Asp 470 475 480 GCA GAA GCT CTC GTT GTG GAG GCA AAG AAG TGG ACA GCA GTG CCA TCG 1663 Ala Glu Ala Leu Val Val Glu Ala Lys Lys Trp Thr Ala Val Pro Ser 485 490 495 CAG CAC ATG TGT GTG GCC GCC TCG GAC AAG AGA CCC AGG AGC ATC CCC 1711 Gin His Met Cys Val Ala Ala Ser Asp Lys Arg Pro Arg Ser He Pro 500 505 510 TTA GTG CAG GTG CTG CGG ACT ACG GQC CTG ACC AGC GCC TGC GCG GAG 1759 Leu Val Gin Val Leu Arg Thr Thr Ala Leu Thr Ser Ala Cys Ala Glu 515 520 525 530 CAC TCG GAC CAG CGG GTG GTC TAC TTG GAG CAC GTG GTG GTT CGC ACC 1807 His Ser Asp Gin Arg Val Val Tyr Leu Glu His Val Val Val Arg Thr 535 540 545 TCC ATC TCA CAC CCA CGC CGA GGA GAC CTC CAG ATC TAC CTG GTT TCT 1855 Ser He Ser His Pro Arg Arg Gly Asp Leu Gin He Tyr Leu Val Ser . 550 555 560 CCC TCG GGA ACC AAG TCT CAA CTT TTG GCA AAG AGG TTG CTG GAT CTT 1903 Pro Ser Gly Thr Lys Ser Gin Leu Leu Ala Lys Arg Leu Leu Asp Leu 565, 570 575 TCC AAT GAA GGG TTT ACA AAC TGG GAA TTC ATG ACT GTC CAC TGC TGG 1951 Ser Asn Glu Gly Phe Thr Asn Trp Glu Phe Met Thr Val His Cys Trp 580 585 590 GGA GAA AAG GCT GAA GGG CAG TGG ACC TTG GAA ATC CAA GAT CTG CCA 1999 Gly Glu Lys Ala Glu Gly Gin Trp Thr Leu Glu He Gin Asp Leu Pro 595 600 605 610 TCC CAG GTC CGC AAC CCG GAG AAG CAA GGG AAG TTG AAA GAA TGG AGC 2047 Ser Gin Val Arg Asn Pro Glu Lys Gin Gly Lys Leu Lys Glu Trp Ser 615 620 625 CTC ATA CTG TAT GGC ACA GCA GAG CAC CCG TAC CAC ACC TTC AGT GCC 2095 Leu He Leu Tyr Gly Thr Ala Glu His Pro Tyr His Thr Phe Ser Ala 630 635 640 CAT CAG TCC CGC TCG CGG ATG CTG GAG CTC TCA GCC CCA GAG CTG GAG 2143 His Gin Ser Arg Ser Arg Met Leu Glu Leu Ser Ala Pro Glu Leu Glu 645 650 655 CCA CCC AAG GCT GCC CTG TCA CCC TCC CAG GTG GAA GTT CCT GAA GAT 2191 Pro Pro Lys Ala Ala Leu Ser Pro Ser Gin Val Glu Val Pro Glu Asp 660 665 670 GAG GAA GAT TAC ACA GCT CAA TCC ACC CCA GGC TCT GCT AAT ATT TTA 2239 Glu Glu Asp Tyr Thr Ala Gin Ser Thr Pro Gly Ser Ala Asn He Leu 675 680 685 690 SUBSTITUTE SHEET 2287 2335 2383 2431 2479 2527 2575 2623 2671 2719 2767 2815 2863 2911 2959 SUBSTITUTE SHEET ACC AAC CAC ACG TGC AGC AAC GCT GAC GAG ACA TTC TGC GAG ATG GTG 3007 Thr Asn His Thr Cys Ser Asn Ala Asp Glu Thr Phe Cys Glu Met Val 935 940 945 AAG TCC AAC CGG CTG TGC GAA CGG AAG CTC TTC ATT CAG TTC TGC TGC 3055 Lys Ser Asn Arg Leu Cys Glu Arg Lys Leu Phe He Gin Phe Cys Cys 950 955 960 CGC ACG TGC CTC CTG GCC GGG T AAGGGTGCCT AGCTGCCCAC AGAGGGCAGG 3107 Arg Thr Cys Leu Leu Ala Gly 965 CACTCCCATC CATCCATCCG TCCACCTTCC TCCAGACTGT CGGCCAGAGT CTGTTTCAGG 3167 AGCGGCGCCC TGCACCTGAC AGCTTTATCT CCCCAGGAGC AGCATCTCTG AGCACCCAAG 3227 CCAGGTGGGT GGTGGCTCTT AAGGAGGTGT TCCTAAAATG GTGATATCCT CTCAAATGCT 3287 GCTTGTTGGC TCCAGTCTTC CGACAAACTA ACAGGAACAA AATGAATTCT GGGAATCCAC 3347 AGCTCTGGCT TTGGAGCAGC TTCTGGGACC ATAAGTTTAC TGAATCTTCA AGACCAAAGC 3407 AGAAAAGAAA GGCGCTTGGC ATCACACATC ACTCTTCTCC CCGTGCTTTT CTGCGGCTGT 3467 GTAGTAAATC TCCCCGGCCC AGCTGGCGAA CCCTGGGCCA TCCTCACATG TGACAAAGGG 3527 CCAGCAGTCT ACCTGCTCGT TGCCTGCCAC TGAGCAGTCT GGGGACGGTT TGGTCAGACT 3587 ATAAATAAGA TAGGTTTGAG GGCATAAAAT GTATGACCAC TGGGGCCGGA GTATCTATTT 3647 CTACATAGTC AGCTACTTCT GAAACTGCAG CAGTGGCTTA GAAAGTCCAA TTCCAAAGCC 3707 AGACCAGAAG ATTCTATCCC CCGCAGCGCT CTCCTTTGAG CAAGCCGAGC TCTCCTTGTT 3767 ACCGTGTTCT GTCTGTGTCT TCAGGAGTCT CATGGCCTGA ACGACCACCT CGACCTGATG 3827 CAGAGCCTTC TGAGGAGAGG CAACAGGAGG CATTCTGTGG CCAGCCAAAA GGTACCCCGA 3887 TGGCCAAGCA ATTCCTCTGA ACAAAATGTA AAGCCAGCCA TGCATTGTTA ATCATCCATC 3947 ACTTCCCATT TTATGGAATT GCTTTTAAAA TACATTTGGC CTCTGCCCTT CAGAAGACTC 4007 GTTTTTAAGG TGGAAACTCC TGTGTCTGTG TATATTACAA GCCTACATGA CACAGTTGGA 4067 TTTATTCTGC CAAACCTGTG TAGGCATTTT ATAAGCTACA TGTTCTAATT TTTACCGATG 4127 TTAATTATTT TGACAAATAT TTCATATATT TTCATTGAAA TGCACAGATC TGCTTGATCA 4187 ATTCCCTTGA ATAGGGAAGT AACATTTGCC TTAAATTTTT TCGACCTCGT CTTTCTCCAT 4247 ATTGTCCTGC TCCCCTGTTT GACGACAGTG CATTTGCCTT GTCACCTGTG AGCTGGAGAG 4307 AACCCAGATG TTGTTTATTG AATCTACAAC TCTGAAAGAG AAATCAATGA AGCAAGTACA 4367 ATGTTAACCC TAAATTAATA AAAGAGTTAA CATCCC 4403 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 969 amino acids SUBSTITUTE SHEET (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Pro Pro Arg Ala Pro Pro Ala Pro Gly Pro Arg Pro Pro Pro Arg 1 5 10 15 Ala Ala Ala Ala Thr Asp Thr Ala Ala Gly Ala Gly Gly Ala Gly Gly 20 25 30 Ala Gly Gly Ala Gly Gly Pro Gly Phe Arg Pro Leu Ala Pro Arg Pro 35 40 45 Trp Arg Trp Leu Leu Leu Leu Ala Leu Pro Ala Ala Cys Ser Ala Pro 50 55 60 Pro Pro Arg Pro Val Tyr Thr Asn His Trp Ala Val Gin Val Leu Gly 65 70 75 80 Gly Pro Ala Glu Ala Asp Arg Val Ala Ala Ala His Gly Tyr Leu Asn 85 90 95 Leu Gly Gin He Gly Asn Leu Glu Asp Tyr Tyr His Phe Tyr His Ser 100 105 110 Lys Thr Phe Lys Arg Ser Thr Leu Ser Ser Arg Gly Pro His Thr Phe 115 120 125 Leu Arg Met Asp Pro Gin Val Lys Trp Leu Gin Gin Gin Glu Val Lys 130 135 140 Arg Arg Val Lys Arg Gin Val Arg Ser Asp Pro Gin Ala Leu Tyr Phe 145 150 155 160 Asn Asp Pro He Trp Ser Asn Met Trp Tyr Leu His Cys Gly Asp Lys 165 170 175 Asn Ser Arg Cys Arg Ser Glu Met Asn Val Gin Ala Ala Trp Lys Arg 180 185 190 Gly Tyr Thr Gly Lys Asn Val Val Val Thr He Leu Asp Asp Gly He 195 200 205 Glu Arg Asn His Pro Asp Leu Ala Pro Asn Tyr Asp Ser Tyr Ala Ser 210 215 220 Tyr Asp Val Asn Gly Asn Asp Tyr Asp Pro Ser Pro Arg Tyr Asp Ala 225 _ 230 235 240 Ser Asn Glu Asn Lys His Gly Thr Arg Cys Ala Gly Glu Val Ala Ala 245 250 255 Ser Ala Asn Asn Ser Tyr Cys He Val Gly He Ala Tyr Asn Ala Lys 260 265 270 He Gly Gly He Arg Met Leu Asp Gly Asp Val Thr Asp Val Val Glu 275 280 285 SUBSTITUTE SHEET Ala Lys Ser Leu Gly He Arg Pro Asn Tyr He Asp He Tyr Ser Ala 290 295 300 Ser Trp Gly Pro Asp Asp Asp Gly Lys Thr Val Asp Gly Pro Gly Arg 305 310 315 320 Leu Ala Lys Gin Ala Phe Glu Tyr Gly He Lys Lys Gly Arg Gin Gly 325 330 335 Leu Gly Ser He Phe Val Trp Ala Ser Gly Asn Gly Gly Arg Glu Gly 340 345 350 Asp Tyr Cys Ser Cys Asp Gly Tyr Thr Asn Ser He Tyr Thr He Ser 355 360 365 Val Ser Ser Ala Thr Glu Asn Gly Tyr Lys Pro Trp Tyr Leu Glu Glu 370 375 , 380 Cys Ala Ser Thr Leu Ala Thr Thr Tyr Ser Ser Gly Ala Phe Tyr Glu 385 390 395 400 Arg Lys He Val Thr Thr Asp Leu Arg Gin Arg Cys Thr Asp Gly His 405 410 415 Thr Gly Thr Ser Val Ser Ala Pro Met Val Ala Gly He He Ala Leu 420 425 430 Ala Leu Glu Ala Asn Ser Gin Leu Thr Trp Arg Asp Val Gin His Leu 435 440 445 Leu Val Lys Thr Ser Arg Pro Ala His Leu Lys Ala Ser Asp Trp Lys 450 455 460 Val Asn Gly Ala Gly His Lys Val Ser His Phe Tyr Gly Phe Gly Leu 465 470 475 480 Val Asp Ala Glu Ala Leu Val Val Glu Ala Lys Lys Trp Thr Ala Val 485 490 495 Pro Ser Gin His Met Cys Val Ala Ala Ser Asp Lys Arg Pro Arg Ser 500 505 510 He Pro Leu Val Gin Val Leu Arg Thr Thr Ala Leu Thr Ser Ala Cys 515 520 525 Ala Glu His Ser Asp Gin Arg Val Val Tyr Leu Glu His Val Val Val 530 535 540 Arg Thr Ser He Ser His Pro Arg Arg Gly Asp Leu Gin He Tyr Leu 545 550 555 560 Val Ser Pro Ser Gly Thr Lys Ser Gin Leu Leu Ala Lys Arg Leu Leu 565 570 575 Asp Leu Ser Asn Glu Gly Phe Thr Asn Trp Glu Phe Met Thr Val His 580 585 590 Cys Trp Gly Glu Lys Ala Glu Gly Gin Trp Thr Leu Glu He Gin Asp 595 600 605 Leu Pro Ser Gin Val Arg Asn Pro Glu Lys Gin Gly Lys Leu Lys Glu 610 615 620 SUBSTITUTESHEET Trp Ser Leu He Leu Tyr Gly Thr Ala Glu His Pro Tyr His Thr Phe 625 630 635 640 Ser Ala His Gin Ser Arg Ser Arg Met Leu Glu Leu Ser Ala Pro Glu 645 650 655 Leu Glu Pro Pro Lys Ala Ala Leu Ser Pro Ser Gin Val Glu Val Pro 660 665 670 Glu Asp Glu Glu Asp Tyr Thr Ala Gin Ser Thr Pro Gly Ser Ala Asn 675 680 685 He Leu Gin Thr Ser Val Cys His Pro Glu Cys Gly Asp Lys Gly Cys 690 695 700 Asp Gly Pro Asn Ala Asp Gin Cys Leu Asn Cys Val His Phe Ser Leu 705 710 , 715 720 Gly Ser Val Lys Thr Ser Arg Lys Cys Val Ser Val Cys Pro Leu Gly 725 730 735 Tyr Phe Gly Asp Thr Ala Ala Arg Arg Cys Arg Arg Cys His Lys Gly 740 745 750 Cys Glu Thr Cys Ser Ser Arg Ala Ala Thr Gin Cys Leu Ser Cys Arg 755 760 765 Arg Gly Phe Tyr His His Gin Glu Met Asn Thr Cys Val Thr Leu Cys 770 775 780 Pro Ala Gly Phe Tyr Ala Asp Glu Ser Gin Lys Asn Cys Leu Lys Cys 785 790 795 800 His Pro Ser Cys Lys Lys Cys Val Asp Glu Pro Glu Lys Cys Thr Val 805 810 815' Cys Lys Glu Gly Phe Ser Leu Ala Arg Gly Ser Cys He Pro Asp Cys 820 825 830 Glu Pro Gly Thr Tyr Phe Asp Ser Glu Leu He Arg Cys Gly Glu Cys 835 840 845 His His Thr Cys Gly Thr Cys Val Gly Pro Gly Arg Glu Glu Cys He 850 855 860 His Cys Ala Lys Asn Phe His Phe His Asp Trp Lys Cys Val Pro Ala 865 870 875 880 Cys Gly Glu Gly Phe Tyr Pro Glu Glu Met Pro Gly Leu Pro His Lys 885 890 895 Val Cys Arg Arg Cys Asp Glu Asn Cys Leu Ser Cys Ala Gly Ser Ser 900 905 910 Arg Asn Cys Ser Arg Cys Lys Thr Gly Phe Thr Gin Leu Gly Thr Ser 915 920 925 Cys He Thr Asn His Thr Cys Ser Asn Ala Asp Glu Thr Phe Cys Glu 930 935 940 Met Val Lys Ser Asn Arg Leu Cys Glu Arg Lys Leu Phe He Gin Phe 945 950 955 960 SUBSTITUTE SHEET Cys Cys Arg Thr Cys Leu Leu Ala Gly 965 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 636 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (cDNA) (ix) FEATURE: ' (A) NAME/KEY: CDS (B) LOCATION: 1..58 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: GGT CAT AAA GGT GCG GCA GTG GCG TTC TGG TGG ACC ATT GGG TGG CCC 48 Gly His Lys Gly Ala Ala Val Ala Phe Trp Trp Thr He Gly Trp Pro 1 5 10 15 TGG AAT GTG T AGGAAGGGGT GTCATGAATT CCTTAAAAGG ACTCTCCAAA 98 Trp Asn Val TAGCATTAGT TGTTATTATT AACTTAAAAG GACTCTCCAA ATAGCATTAG TTGTTATTAT 158 TAATTGTGTG TCACAAGAAT TTAAAACGCA TGTGCAGCTA TTTAAGAAAA GTATCCCGGA 218 AGCTCACAGT GACATTACGG AAGAACCCTC AGGTCACAAG AGTCTGGGGT CTCCTATACT 278 CTATAACTTT GGCCACACCG AGACACCACC TATACCAATA TTTACTCATA GTTCTCTTTA 338 AGCCAGGAGC AATGACGTGT GCCTATAGTC GCAGCTACTA GGGAAGTTGA GGCAGGAGGA 398 TTGCTTGAGC CCAGGAATTT GAGTCTAGCC TGGACAACAC AGCAGGACTC CATCTCTTAA 458 AAAAAAAATT ACTTCCCCCA CTACTTTTTT TGACATAAAA AAATGTATTT TAAAAGGAAA 518 CTGTACTACA TCTAGTTAAT CATAGGTTTG ATATGTAGTT ACGTATTTTT TCTAATGTGC 578 ATTAAAACAA ATCCATAATT ATTAAAATAA ATGTTGTTTG TGTGCCAAAA AAAAAAAA 636 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: SUBSTITUTE SHEET Gly His Lys Gly Ala Ala Val Ala Phe Trp Trp Thr He Gly Trp Pro 1 5 10 15 Trp Asn Val (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 148 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) _ (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 18..131 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: GGCCTGTCTT TTCAGTT AGC CAT TTC TAT GGA TTT GGT TTG GTG GAC GCA 50 Ser His Phe Tyr Gly Phe Gly Leu Val Asp Ala 1 5 10 GAA GCT CTC GTT GTG GAG GCA AAG AAG TGG ACA GCA GTG CCA TCG CAG 98 Glu Ala Leu Val Val Glu Ala Lys Lys Trp Thr Ala Val Pro Ser Gin 15 20 25 CAC ATG TGT GTG GCC GCC TCG GAC AAG AGA CCC AGGTAAGGCT CTGCTGT 148 His Met Cys Val Ala Ala Ser Asp Lys Arg Pro 30 35 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Ser His Phe Tyr Gly Phe Gly Leu Val Asp Ala Glu Ala Leu Val Val 1 5 10 15 Glu Ala Lys Lys Trp Thr Ala Val Pro Ser Gin His Met Cys Val Ala 20 25 30 Ala Ser Asp Lys Arg Pro 35 SUBSTITUTE SHEET (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 280 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Asn Asp Pro Leu Phe Glu Arg Gin Trp His Leu Val Asn Pro Ser Phe 1 5 10 15 Pro Gly Ser Asp He Asn Val Leu Asp Leu Trp Tyr Asn Asn He Thr 20 , 25 30 Gly Ala Gly Val Val Ala Ala He Val Asp Asp Gly Leu Asp Tyr Glu 35 40 45 Asn Glu Asp Leu Lys Asp Asn Phe Cys Ala Glu Gly Ser Trp Asp Phe 50 55 60 Asn Asp Asn Thr Asn Leu Pro Lys Pro Arg Leu Ser Asp Asp Tyr His 65 70 75 80 Gly Thr Arg Cys Ala Gly Glu He Ala Ala Lys Lys Gly Asn Asn Phe 85 90 95 Cys Gly Val Gly Val Gly Tyr Asn Ala Lys He Ser Gly He Arg He 100 105 110 Leu Ser Gly Asp He Thr Thr Glu Asp Glu Ala Ala Ser Leu He Tyr 115 120 125 Gly Leu Asp Val Asn Asp He Tyr Ser Cys Ser Trp Gly Pro Ala Asp 130 135 140 Asp Gly Arg His Leu Gin Gly Pro Ser Asp Leu Val Lys Lys Ala Leu 145 150 155 160 Val Lys Gly Val Thr Glu Gly Arg Asp Ser Lys Gly Ala He Tyr Val 165 170 175 Phe Ala Ser Gly Asn Gly Gly Thr Arg Gly Asp Asn Cys Asn Tyr Asp 180 185 190 Gly Tyr Thr Asn Ser He Tyr Ser He Thr He Gly Ala He Asp His 195 200 205 Lys Asp Leu His Pro Pro Tyr Ser Glu Gly Cys Ser Ala Val Met Ala 210 215 220 Val Thr Tyr Ser Ser Gly Ser Gly Glu Tyr He His Ser Ser Asp He 225 230 235 240 Asn Gly Arg Cys Ser Asn Ser His Gly Gly Thr Ser Ala Ala Ala Pro 245 250 255 Leu Ala Ala Gly Val Tvr Thr Leu Leu Leu Glu Ala Asn Pro Asn Leu 260 265 270 SUBSTITUTE SHEET Thr Trp Arg Asp Val Gin Tyr Leu 275 280 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 282 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Asp Pro Lys Phe Pro Gin Gin Trp Tyr Leu Ser Gly Val Thr Gin Arg 1 5 10 15 Asp Leu Asn Val Lys Ala Ala Trp Ala Gin Gly Tyr Thr Gly His Gly 20 25 30 He Val Val Ser He Leu Asp Asp Gly He Glu Lys Asn His Pro Asp 35 40 45 Leu Ala Gly Asn Tyr Asp Pro Gly Ala Ser Phe Asp Val Asn Asp Gin 50 55 60 Asp Pro Asp Pro Gin Pro Arg Tyr Thr Gin Met Asn Asp Asn Arg His 65 70 75 80 Gly Thr Arg Cys Ala Gly Glu Val Ala Ala Val Ala Asn Asn Gly Val 85 90 95 Cys Gly Val Gly Val Ala Tyr Asn Ala Arg He Gly Gly Val Arg Met 100 105 110 Leu Asp Gly Glu Val Thr Asp Ala Val Glu Ala Arg Ser Leu Gly Leu 115 120 125 Asn Pro Asn His He His He Tyr Ser Ala Ser Trp Gly Pro Glu Asp 130 135 140 Asp Gly Lys Thr Val Asp Gly Pro Ala Arg Leu Ala Glu Glu Ala Phe 145 150 155 160 Phe Arg Gly Val Ser Gl Gly Arg Gly Gly Leu Gly Ser He Phe Val 165 170 175 Trp Ala Ser Gly Asn Gly Gly Arg Glu His Asp Ser Cys Asn Cys Asp 180 185 190 Gly Tyr Thr Asn Ser He Tyr Thr Leu Ser He Ser Ser Ala Thr Gin 195 200 205 Phe Gly Asn Val Pro Trp Tyr Ser Glu Ala Cys Ser Ser Thr Leu Ala 210 215 220 Thr Thr Tyr Ser Ser Gly Asn Gin Asn Glu Lys Gin He Val Thr Thr 225 230 235 240 SUBSTITUTE SHEET Asp Leu Arg Gin Lys Cys Thr Glu Ser His Thr Gly Thr Ser Ala Ser 245 250 255 Ala Pro Leu Ala Ala Gly He He Ala Leu Thr Leu Glu Ala Asn Lys 260 265 270 Asn Leu Thr Trp Arg Asp Met Gin His Leu 275 280 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 291 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear , (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Asn Asp Pro Leu Phe Thr Lys Gin Trp Tyr Leu He Asn Thr Gly Gin 1 5 10 15 Ala Asp Gly Thr Pro Gly Leu Asp Leu Asn Val Ala Glu Ala Trp Glu 20 25 30 Leu Gly Tyr Thr Gly Lys Gly Val Thr He Gly He Met Asp Asp Gly 35 40 45 He Asp Tyr Leu His Pro Asp Leu Ala Ser Asn Tyr Asn Ala Glu Ala 50 55 60 Ser Tyr Asp Phe Ser Ser Asn Asp Pro Tyr Pro Tyr Pro Arg Tyr Thr 65 70 75 80 Asp Asp Trp Phe Asn Ser His Gly Thr Arg Cys Ala Gly Glu Val Ser 85 90 95 Ala Ala Ala Asn Asn Asn He Cys Gly Val Gly Val Ala Tyr Asn Ser 100 105 110 Lys Val Ala Gly He Arg Met Leu Asp Gin Pro Phe Met Thr Asp He 115 120 125 He Glu Ala Ser Ser He Ser His Met Pro Gin Leu He Asp He Tyr 130 135 140 Ser Ala Ser Trp Gly Pro Thr Asp Asn Gly Lys Thr Val Asp Gly Pro 145 150 155 160 Arg Asp Val Thr Leu Gin Ala Met Ala Asp Gly Val Asn Lys Gly Arg 165 170 175 Gly Gly Lys Gly Ser He Tyr Val Trp Ala Ser Gly Asp Gly Gly Ser 180 185 190 Tvr Asp Asp Cys Asn Cys Asp Gly Tyr Ala Ser Ser Met Trp Thr He 195 200 205 SUBSTITUTE SHEET Ser He Asn Ser Ala He Asn Asp Gly Arg Thr Ala Leu Tyr Asp Glu 210 215 220 Ser Cys Ser Ser Thr Leu Ala Ser Thr Phe Ser Asn Gly Arg Lys Arg 225 230 235 240 Asn Pro Glu Ala Gly Val Ala Thr Thr Asp Leu Tyr Gly Asn Cys Thr 245 250 255 Leu Arg His Ser Gly Thr Ser Ala Ala Ala Pro Glu Ala Ala Gly Val 260 265 270 Phe Ala Leu Ala Leu Glu Ala Asn Leu Gly Leu Thr Trp Arg Asp Met 275 280 285 * Gin His Leu 290 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 289 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: Asn Asp Pro Met Trp Asn Gin Gin Trp Tyr Leu Gin Asp Thr Arg Met 1 5 10 15 Thr Ala Ala Leu Pro Lys Leu Asp Leu His Val He Pro Val Trp Glu 20 25 30 Lys Gly He Thr Gly Lys Gly Val Val He Thr Val Leu Asp Asp Gly 35 40 45 Leu Glu Trp Asn His Thr Asp He Tyr Ala Asn Tyr Asp Pro Glu Ala 50 55 60 Ser Tyr Asp Phe Asn Asp Asn Asp His Asp Pro Phe Pro Arg Tyr Asp 65 70 75 * . 80 Leu Thr Asn Glu Asn Lys His Gly Thr Arg Cys Ala Gly Glu He Ala 85 90 95 Met Gin Ala Asn Asn His Lys Cys Gly Val Gly Val Ala Tyr Asn Ser 100 105 110 Lys Val Gly Gly He Arg Met Leu Asp Gly He Val Thr Asp Ala He 115 120 125 Glu Ala Ser Ser He Gly Phe Asn Pro Gly His Val Asp He Tyr Ser 130 135 140 Ala Ser Trp Gly Pro Asn Asp Asp Gly Lys Thr Val Glu Gly Pro Gly 145 150 155 160 SUBSTITUTE SHEET Arg Leu Ala Gin Lys Ala Phe Glu Tyr Gly Val Lys Gin Gly Arg Gin 165 170 175 Gly Lys Gly Ser He Phe Val Trp Ala Ser Gly Asn Gly Gly Arg Gin 180 185 190 Gly Asp Asn Cys Asp Cys Asp Gly Tyr Thr Asp Ser He Tyr Thr He 195 200 205 Ser He Ser Ser Ala Ser Gin Gin Gly Leu Ser Pro Trp Tyr Ala Glu 210 215 220 Lys Cys Ser Ser Thr Leu Ala Thr Ser Tyr Ser Ser Gly Asp Tyr Thr 225 230 235 240 Asp Gin Arg He Thr Ser Ala Asp Leu His Asn Asp Cys Thr Glu Thr 245 250 255 His Thr Gly Thr Ser Ala Ser Ala Pro Leu Ala Ala Gly He Phe Ala 260 265 270 Leu Ala Leu Glu Ala Asn Pro Asn Leu Thr Trp Arg Asp Met Gin His 275 280 285 Leu (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 287 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Asn Asp Pro He Trp Ser Asn Met Trp Tyr Leu His Cys Gly Asp Lys 1 5 10 15 Asn Ser Arg Cys Arg Ser Glu Met Asn Val Gin Ala Ala Trp Lys Arg 20 25 30 Gly Tyr Thr Gly Lys Asn Val Val Val Thr He Leu Asp Asp Gly He 35 40 45 Glu Arg Asn His Pro Asp Leu Ala Pro Asn Tyr Asp Ser Tyr Ala Ser 50 55 60 Tyr Asp Val Asn Gly Asn Asp Tyr Asp Pro Ser Pro Arg Tyr Asp Ala 65 70 75 80 Ser Asn Glu Asn Lys His Gly Thr Arg Cys Ala Gly Glu Val Ala Ala 85 90 95 Ser Ala Asn Asn Ser Tyr Cys He Val Gly He Ala Tyr Asn Ala Lys 100 105 110 SUBSTITUTE SHEET He Gly Gly He Arg Met Leu Asp Gly Asp Val Thr Asp Val Val Glu 115 120 125 Ala Lys Ser Leu Gly He Arg Pro Asn Tyr He Asp He Tyr Ser Ala 130 135 140 Ser Trp Gly Pro Asp Asp Asp Gly Lys Thr Val Asp Gly Pro Gly Arg 145 150 155 160 Leu Ala Lys Gin Ala Phe Glu Tyr Gly He Lys Lys Gly Arg Gin Gly 165 170 175 Leu Gly Ser He Phe Val Trp Ala Ser Gly Asn Gly Gly Arg Glu Gly 180 185 190 Asp Tyr Cys Ser Cys Asp Gly Tyr Thr Asn Ser He Tyr Thr He Ser 195 200 205 Val Ser Ser Ala Thr Glu Asn Gly Tyr Lys Pro Trp Tyr Leu Glu Glu 210 215 220 Cys Ala Ser Thr Leu Ala Thr Thr Tyr Ser Ser Gly Ala Phe Tyr Glu 225 230 235 240 Arg Lys He Val Thr Thr Asp Leu Arg Gin Arg Cys Thr Asp Gly His 245 250 255 Thr Gly Thr Ser Val Ser Ala Pro Met Val Ala Gly He He Leu Ala 260 265 270 Leu Glu Ala Asn Ser Gin Leu Thr Trp Arg Asp Val Gin His Leu 275 280 285 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: AGATCTGAAT TCGAYGAYGG NAT 23 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: SUBSTITUTE SHEET AGATCTAAGC TTACACCKNG TNCCRTG 27 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: TATTCATTGC CGTTCACGTC GTAG , 24 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: GCTGGCATCA TATCGTGGAG AT 22 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (synthetic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: GGAGGCATAG CGGCGAC 17 SUBSTITUTE SHEET

Claims: CLAIMS WHAT IS CLAIMED IS: 1. An isolated polynucleotide comprising a sequence encoding PACE 4. 2. The polynucleotide according to Claim 1, wherein said sequence encodes a polypeptide having an amino acid sequence at least 90% homologous to an amino acid sequence encoded by the cDNA sequence of Figure 1 (SEQ ID NO: 1). 3. The polynucleotide according to Claim 2, wherein said polynucleotide sequence encodes a polypeptide which has an amino acid sequence identical to the amino acid sequence encoded by the cDNA sequence of Figure 1 (SEQ ID NO: 1). 4. The polynucleotide according to Claim 2, wherein said polynucleotide sequence does not encode a cysteine-rich region. 5. A transformed ceU comprising a recombinant polynucleotide encoding PACE 4 or 4.1, wherein said cell is capable of expressing PACE 4 or 4.1. 6. The ceU according to Claim 5, wherein said ceU is a mammaUan cell. 7. The mammaUan ceU according to claim 6, wherein the said mammaUan cell is a CHO cell. 8. The ceU according to Claim 5, wherein said ceU is an insect cell. 9. The insect ceU according to claim 8, wherein said insect ceU is selected from the group consisting of Aedes aegypti, Autographa calif ornica, Bombyx mori, Drosophila melanogaster, Spodoptera frugiperda, and Trichoplusia ni. SUBSTITUTE SHEET 10. The ceU according to Claim 5, wherein said ceU is a microorganism selected from the group consisting of bacteria and fungi. 11. The microorganism ceU according to Claim 10, wherein said microorganism is yeast 12. A ceU comprising a recombinant polynucleotide encoding a PACE 4 and a heterologous polynucleotide encoding a precursor polypeptide, wherein said precursor polypeptide is a substrate for the encoded PACE 4, and wherein said ceU is capable of expressing the polynucleotides encoding said PACE 4 and said heterologous polypeptide. 13. The ceU according to Claim 12, wherein said encoded PACE 4 and said encoded heterologous precursor polypeptide, when expressed, are secreted into extraceUular medium. 14. The ceU according to Claim 12, wherein said ceU is a mammaUan ceU. 15. The mammaUan ceU according to claim 14, wherein said mammaUan ceU is a CHO ceU. 16. The ceU according to Claim 12, wherein said ceU is an insect ceU. 17. The ceU according to claim 16, wherein said insect ceU is selected from the group consisting of Aedes aegypti, Autographa calif ornica, Bombyx mori, DrosophUa melanogaster, Spodoptera frugiperda, and Trichoplusia ni. 18. The ceU according to claim 12, wherein said ceU is a microorganism selected from the group consisting of bacteria and fungi. 19. The microorganism ceU according to claim 18, wherein said microorganism is yeast SUBSTITUTE SHEET 20. A recombinant expression vector suitable for expression in a ceU comprising a polynucleotide sequence encoding PACE 4 or 4.1, wherein said PACE 4 or 4.1 encoding sequence is operably Unked to a control sequence. 21. The expression vector according to claim 20, wherein said cell is a microorganism selected from the group consisting of bacteria and fungi. 22. The expression vector according to claim 21, wherein said microorganism is yeast. 23. The expression vector according to claim 20, wherein said ceU is a mammaUan ceU. 24. The expression vector according to claim 23, wherein said vector is a recombinant vaccinia virus. 25. The expression vector according to claim 20, wherein said ceU is an insect ceU. 26. The expression vector according to claim 25, wherein said vector is a recombinant baculovirus. 25. A method for producing recombinant PACE 4 or 4.1 comprising incubating the ceU of claim 5 under conditions that aUow expression of the recombinant polynucleotide encoding PACE 4 or 4.1. 26. A method for producing recombinant PACE 4 or 4.1, comprising: (a) providing a mammaUan ceU transformed by the recombinant expression vector of claim 23, wherein the vector contains control sequences for expression that are compatible with the mammaUan cell; and (b) incubating the mammalian ceU under conditions that aUow transformation with the expression vector. SUBSTITUTE SHEET 27. A method for producing recombinant PACE 4 or 4.1, comprising: (a) providing a microorganism transformed by the expression vector of claim 21, wherein the vector contains control sequences for expression which are compatible with the microorganism; and (b) incubating the microorganism under conditions which aUow transformation with the expression vector. 28. A method for producing a desired mature polypeptide comprising incubating the ceU according to claim 12 under conditions that aUow the expression of (1) recombinant PACE 4 or 4.1 and (2) the heterologous precursor polypeptide. 29. A method for producing a desired mature polypeptide comprising incubating the ceU according to claim 13 under conditions that aUow expression and secretion of (1) recombinant PACE 4 or 4.1 and (2) the heterologous precursor polypeptide. 30. A composition comprising substantiaUy pure PACE 4 polypeptide. 31. The composition of Claim 30, wherein the sequence of said PACE 4 polypeptide is at least 90% homologous to the polypeptide sequence of Figure 1 (SEQ ID NO: 1). 32. The composition of Claim 30, wherein the sequence of said PACE 4 polypeptide is identical to the polypeptide sequence of Figure 1 (SEQ ID NO: 1). 33. A composition comprising substantiaUy pure PACE 4.1 polypeptide. 34. The composition of Claim 33, wherein the sequence of said PACE 4.1 polypeptide is at least 90% homologous to the polypeptide sequence of Figure 2 (SEQ ED NO: 3) taken with Figure 1 (SEQ ID NO: 1). SUBSTITUTE SHEET 35. The composition of Claim 33, wherein the sequence of said PACE 4.1 polypeptide is identical to the polypeptide sequence of Figure 2 (SEQ ID NO: 3) taken with Figure 1 (SEQ ID NO: 1). 36. A method for reducing blood pressure in a mammal comprising administering to said mammal an inhibiting compound in an amount effective to inhibit the conversion of prorenin to renin by PACE 4 or 4.1. 37. The method of Claim 36, wherein said PACE 4 or 4.1 inhibiting compound is α,-antitrypsin or a mutant thereof. 38. A method of inhibiting coagulation of blood comprising administering to a mammal a coagulation inhibiting amount of a composition comprising PACE 4 or 4.1. 39. A pharmaceutical composition for inhibiting blood coagulation comprising a coagulation inhibiting amount of PACE 4 or 4.1 in a physiologicaUy compatible matrix. 40. An isolated oUgonucleotide comprising at least 15 consecutive nucleotides from the sequence of Figure 1, wherein said at least 15 consecutive nucleotides of said oUgonucleotide are not consecutively present in the sequences encoding KEX2, PC1/PC3, furin/PACE, or PC2. 41. An isolated polypeptide comprising a domain having an amino acid sequence at least 90% homologous to the amino acid sequence from Cys695 to Cys965 of the cysteine rich region of Figure 1 (SEQ ID NO: 1). 42. A fusion protein comprising a domain having an amino acid sequence at least 90% homologous to the amino acid sequence from Cys695 to Cys965 of the cystine rich region of PACE 4 and a functional domain from a heterologous protein. SUBSTITUTE SHEET

Inventors: BARR PHILIP J, KIEFER MICHAEL C, BARR, PHILIP, J., KIEFER, MICHAEL, C.
Applicants: CHIRON CORP, CHIRON CORPORATION
Application year: 1993
Main classification: C12N9
IPC codes: A61K38, C07H21, C12N1, C12N5, C12N9, C12N15, C12R1